Effects of Maternal Folate Levels and Prenatal Alcohol Exposure on Fetal Growth, Infant Outcomes and Later Development by Gailey, Amanda R.
Georgia State University
ScholarWorks @ Georgia State University
Public Health Theses School of Public Health
8-11-2015
Effects of Maternal Folate Levels and Prenatal
Alcohol Exposure on Fetal Growth, Infant
Outcomes and Later Development
Amanda R. Gailey
Georgia State University
Follow this and additional works at: https://scholarworks.gsu.edu/iph_theses
This Thesis is brought to you for free and open access by the School of Public Health at ScholarWorks @ Georgia State University. It has been accepted
for inclusion in Public Health Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.
Recommended Citation
Gailey, Amanda R., "Effects of Maternal Folate Levels and Prenatal Alcohol Exposure on Fetal Growth, Infant Outcomes and Later
Development." Thesis, Georgia State University, 2015.
https://scholarworks.gsu.edu/iph_theses/419
i 
 
 
 
 
 
Effects of Maternal Folate Levels and Prenatal Alcohol Exposure on Fetal Growth, Infant 
Outcomes and Later Development 
By 
 
 
Amanda R. Gailey 
M.A.T., Piedmont College 
B.S., University of Georgia 
 
 
 
 
A Thesis Submitted to the Graduate Faculty of Georgia State University in Partial Fulfillment of 
the Requirements for the Degree 
 
MASTER OF PUBLIC HEALTH 
ATLANTA, GEORGIA 
30303 
  
ii 
 
 
Effects of Maternal Folate Levels and Prenatal Alcohol Exposure on Fetal Growth, Infant 
Outcomes and Later Development 
 
By 
 
Amanda R. Gailey 
 
 
 
 
Approved: 
 
Daniel Whitaker, PhD 
Committee Chair 
 
 
Claire D. Coles, PhD 
Committee Member 
 
July 27, 2015 
  
iii 
 
Acknowledgements 
 I would like to thank my thesis chair, Dr. Daniel Whitaker, and committee member, Dr. 
Claire Coles, for their continued support and guidance throughout this process.  I would also like 
to thank Dr. Julie Kable for providing additional support during the analysis process.  Thank you 
to the Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) for their 
continued commitment to research in the field of FASD’s.  Thank you to the faculty of 
University of California San Diego, including Dr. Christina Chambers, Principal Investigator of 
the CIFASD project, and Jordan Schafer for providing data and support.  Thank you to 
participating families and staff in Rivne and Khmelnytsky, Ukraine and OMNI-Net, Ukraine for 
your contributions to the project.  Thank you to the faculty and staff of the Emory University 
Center for Maternal Substance Abuse and Child Development (MSACD) for their 
encouragement and advice.  Thank you to Georgia State University’s School of Public Health for 
the challenge and opportunity to pursue my passion for public health.  Thank you to Dr. Michael 
Eriksen for the opportunity to learn from his expertise in the field and for his continued 
encouragement and support.  Finally, I would like to thank my parents and siblings for always 
supporting my dreams.  
iv 
 
Abstract 
Objectives 
Prenatal alcohol exposure can lead to fetal alcohol spectrum disorders (FASD), which include a 
broad range of cognitive, growth, behavior, and physical abnormalities.  Early detection of the 
teratogenic effects of prenatal alcohol exposure is necessary to identify early interventions. The 
aim of this study is to identify the effects of prenatal alcohol exposure on growth and infant 
development, to determine if ultrasound imaging can be used as an early identification tool, and 
to determine if maternal folate supplementation can mitigate the detrimental effects on growth 
and infant development.  
Methods 
A prospective cohort study and randomized trial from 2008 to 2014 conducted in two sites of 
Western Ukraine was analyzed.  A sample of pregnant women who reported moderate-to-heavy 
alcohol consumption during pregnancy, and a sample reporting little-to-no alcohol use during 
pregnancy participated in a comprehensive maternal interview and screening process.  Women 
were further randomized into micronutrient supplementation groups.  Standard ultrasound 
examinations during pregnancy including study specific brain growth measurements, along with 
blood and urine samples were obtained during follow-up visits.  A biometric screening was 
conducted at birth, along with Bayley Scales of Infant Development-II Mental Development 
Index (MDI) and Psychomotor Development Index (PDI) assessments at 6 and 12 months of age. 
Results 
Estimated fetal weight (EFW), abdominal circumference (AC), biparietal diameter (BPD), 
transverse cerebellar diameter (TCD), occipitofrontal diameter (OFD), caval-calvarial distance 
(CCD), and orbital diameter (OD) were significantly reduced by alcohol exposure at third 
trimester ultrasound (p<0.05).  Birth weight, length and head circumference as well as Bayley 
MDI and PDI scores at 6 and 12 months of age were significantly reduced by alcohol exposure 
(p<0.05).  Generalized linear modeling was used to examine the relationship between outcomes 
significantly associated with alcohol exposure and multivitamin supplementation (MVM), 
absolute ounces of alcohol per day at conception (AA/day), and serum folate concentration.  
MVM was significantly associated with increased EFW at third trimester (X
2
(7)=18.044, 
p=0.012), AC at third trimester (X
2
(5)=17.955, p=0.003), and birth weight (X
2
(6)=75.058, 
p<0.001).  Serum folate concentration during third trimester was significantly associated with 
increased Bayley MDI scores at 6 months of age (X
2
(11)=63.051, p<0.001).   
 Conclusions 
Significant reductions in fetal growth measurements during third trimester ultrasound suggest 
that the effects of prenatal alcohol exposure may be detectable in late pregnancy.  Significant 
associations between multivitamin supplementation and specific growth measurements suggest 
that micronutrient supplementation during pregnancy, including high doses of folate, may be an 
early intervention to reduce the harmful effects of prenatal alcohol exposure.  Further studies are 
needed to identify the specific micronutrients producing these effects, and to assess the 
appropriate level of these micronutrients necessary to provide the greatest benefit without 
exceeding the safe limit.   
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INTRODUCTION 
1.1 Background 
Fetal Alcohol Syndrome (FAS) is the most severe form of a group of disorders known as 
Fetal Alcohol Spectrum Disorders (FASDs).  The disorder was first recognized in 1973 by Jones 
and colleagues and remains one of the leading causes of developmental disabilities worldwide.
1,2
 
Alcohol passes to the fetus through the blood stream, and currently there is no known safe level 
of alcohol use during pregnancy.
3 
 The estimated prevalence of FAS in the United States ranges 
from 0.2 to 1.5 infants for every 1,000 live births.  The full range of FASD’s are estimated to 
affect as many as 2% to 5% of the population in the United States and Western European 
Countries.
4
   FAS is characterized by four broad areas of clinical features including abnormal 
facial features (smooth philtrum, short palpebral fissures, and thin upper lip), growth retardation, 
central nervous system dysfunction, and alcohol use during pregnancy.
5
  The developmental 
outcomes can range from mild cognitive deficits to severe impairment, and can result in severe 
problems in memory, executive function, and adaptive behavior.
5,6,7,8,9 
  
1.2 Nutrition and FASD’s 
Proper maternal nutrition is necessary for optimal fetal growth.  Women with poor 
nutritional status during pregnancy can give birth to children with low birth weight, physical 
abnormalities, delayed cognitive development, and poor overall health.  Alcohol use during 
pregnancy can displace essential nutrients and deprive the developing fetus of the nutrition 
necessary for proper growth and development.
10
 Micronutrients such as vitamin A, DHA, zinc, 
calcium, folate, and choline serve a variety of roles in fetal development.  Animal models using 
micronutrient supplementation have shown beneficial results in prevention of fetal alcohol 
effects.  Human studies are needed to examine the association between micronutrient 
2 
 
supplementation and FASD outcomes.  Maternal supplementation with these micronutrients has 
been the focus of recent research as part of the Collaborative Initiative on Fetal Alcohol 
Spectrum Disorders (CIFASD) in Ukraine.
11
 The current project aims to examine the role of 
maternal nutrition on FASD outcomes.     
1.3 Alcohol Exposure and Growth 
Alcohol exposure can affect prenatal and postnatal growth including height, weight, head 
circumference, and brain growth.   The severity of growth restriction can vary with timing and 
quantity of exposure.  Heavy alcohol exposure and binge drinking have the greatest effect on 
preterm birth and growth restriction, with several studies showing a dose-response relationship 
between alcohol consumption and preterm birth, small birth size, and low birth weight.
12,13-15
  
The timing of alcohol exposure necessary to produce effects is widely debated, with studies 
showing a significant association between heavy alcohol exposure in second trimester and small 
birth size, and no association between alcohol exposure in first trimester and birth size.
14
  
Alcohol exposure affects overall head circumference as well as individual structures in a variety 
of regions of the brain.  These regions include the cerebellum, the corpus callosum, the basal 
ganglia, and the frontal cortex.
16
 Imaging techniques such as magnetic resonance imaging (MRI) 
have shown significant reductions in brain size and shape, reductions in frontal lobe and basal 
ganglia size, and reduction in cerebellar volume with prenatal alcohol exposure.
17 
Ultrasound 
technology could be used as an early predictor of the effects of prenatal alcohol exposure on the 
brain.  Few studies examine this effect and show conflicting results with one study showing no 
association between alcohol exposure and ultrasound measures of brain growth, and others 
showing a significant association between ultrasound measures of frontal lobe size in utero in 
alcohol exposed groups.
18,19,20
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1.4 Alcohol Exposure and Development 
The impact of fetal alcohol exposure includes growth restriction, diminished cognitive 
ability, physical malformations, and behavior abnormalities and extends throughout the lifetime 
of an individual.  Many neurological and behavioral abnormalities can result from prenatal 
alcohol exposure including intellectual performance, attention, learning and memory, language, 
executive functioning, fine and gross motor skills, social skills, and adaptive behavior.
17,21 
 
Children with FASD’s are at an increased risk for seizure disorders, cerebral palsy, and visual-
motor deficits.
5
 These abnormalities result in poor educational outcomes, communication 
deficits, and poor reasoning and judgment.  There is no cure for FASD’s, however, educational 
and environmental interventions can improve development.  Treatment options include 
medications for some symptoms, behavior and education therapy, parent training, and special 
education and social services.
2
   
1.4 Purpose of Study 
The teratogenic effects of alcohol on physical features, growth, cognition, behavior, and 
infant outcomes have been studied extensively since first discovered in 1973 by Jones and 
colleagues.
1
 The consequences of prenatal alcohol exposure are well known, and extend into 
adulthood.  Early diagnosis of FASD’s is necessary to ensure proper educational interventions 
and prevent adverse outcomes later in life.
22
 Imaging techniques such as magnetic resonance 
imaging (MRI) and prenatal ultrasounds have shown promise in detecting brain structure 
abnormalities that may result from alcohol exposure.  The effect of prenatal alcohol exposure on 
cognition and postnatal growth restriction can cause lasting effects.  Folate has demonstrated the 
ability to mitigate the effects of prenatal alcohol exposure on development.  The purpose of this 
study is to identify the effects of prenatal alcohol exposure on prenatal and postnatal growth and 
4 
 
infant development using ultrasound imaging. The results have implications for whether 
ultrasound can be used as an early identification tool for prenatal alcohol effects, and whether if 
maternal folate supplementation can mitigate the detrimental effects of prenatal alcohol exposure 
on growth and infant development.  
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REVIEW OF THE LITERATURE 
2.1 Prevalence and Characteristics of FASD’s 
 The prevalence of FASD’s is difficult to determine due to the complex nature of the 
diagnosis.  Centers for Disease Control and Prevention (CDC) studies using medical records 
have estimated the prevalence of FAS to range from 0.2 to 1.5 infants for every 1,000 live 
births.
23
 Another CDC study has estimated approximately 0.3 out of every 1,000 children aged 7-
9 suffers from FAS.
24
 Additional studies estimate the full range of FASD’s to be as high as 20 to 
50 out of 1,000 school children in the United States and Western Europe.
25
  Studies have shown 
that approximately 7.6% of pregnant women in the U.S. report using alcohol during pregnancy 
and 1.4% of pregnant women report binge drinking in the past 30 days.
26,27
  However, the true 
prevalence of drinking during pregnancy is likely underreported due to the stigma associated 
with it.  Fetal alcohol syndrome is estimated to cost an individual approximately $2 million over 
their lifetime, and is estimated to cost the United States over $4 billion annually.
28
  
Globally, the issue is more complex due to limited resources, lack of surveillance and 
underreporting.  In South Africa the prevalence of FAS ranges from 40.5 to 46.4 out of every 
1,000 children aged 5-9 years according to one study conducted in a small community in the 
Western Cape.
29
 Additional studies in South Africa estimate the prevalence ranges from 19 to 
89.2 children out of every 1,000.
30,31
 In Australia one study indicated that approximately 60% of 
non-indigenous women reported drinking during pregnancy.
32
  A separate national survey 
indicated that approximately 20% of indigenous Australian women reported alcohol use during 
pregnancy.
33,34
  The prevalence of FASD’s are estimated to be 0.01 to 1.7 for every 1,000 live 
births in Australia, however these estimates likely underestimate the true prevalence due to lack 
of routine assessment and screening, and a lack of national diagnostic criteria.
33
  In Ukraine, 
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heavy episodic drinking is common among women with 92.7% of women reporting being ever-
drinkers in one study.  The same study indicated that 54.8% of ever drinking women reported 
drinking in the month around conception, and 46.3% continued to drink during pregnancy.
35
   
The characteristics of fetal alcohol syndrome include facial, growth, and central nervous 
system abnormalities when prenatally exposed to alcohol.  Facial dysmorphia includes three 
sentinel facial features including smooth philtrum, thin vermillion border, and small palpebral 
fissures.
5,7,8,9
 Facial dysmorphia must be present in all three sentinel features with palpebral 
fissure length at or below the 10
th
 percentile, adjusted for gestation, age, sex and race, and 
philtrum and upper vermillion ranked at a 4 or 5 on the Lip-Philtrum Guide.
5,9,36
  Growth 
retardation is determined by prenatal or postnatal height or weight at or below the 10
th
 percentile, 
adjusted for gestation, age, sex and race.
5,36,37,38,39
  Central nervous system abnormalities include 
structural abnormalities observed through imaging or head circumference at or below the 10
th
 
percentile adjusted for age and sex, neurological problems including soft neurological signs, and 
deficits in cognitive ability or performance.
5
  Additional diagnoses in the FASD spectrum 
include partial FAS (pFAS), characterized by at least two of the three criteria above in the 
presence of confirmed alcohol exposure, and Alcohol Related Neurodevelopmental Disorder 
(ARND), characterized by cognitive deficits when alcohol exposure is confirmed.
40
   
2.2 Prenatal Alcohol Exposure and Fetal Growth 
 Prenatal and postnatal growth deficiency was first recognized in patients with prenatal 
alcohol exposure in 1973 by Jones and colleagues.
1
  The primary growth parameters associated 
with fetal alcohol syndrome include height, weight, and head circumference.
5
  The severity of 
growth retardation varies by timing and quantity of alcohol exposure.  There are conflicting 
results on the effect of drinking low-to-moderate amounts of alcohol on fetal growth and preterm 
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birth.  A systematic review by Henderson, et al. found inconsistent evidence with some studies 
showing a protective effect on growth, and others showing a detrimental effect on growth.
41 
 A 
cohort study from Western Australia reported little difference in infant outcomes with low-to-
moderate drinking compared to those who did not drink during pregnancy.  Binge drinking and 
heavy drinking in this study were significantly associated with preterm birth and small for 
gestational age, however, this association was eliminated after controlling for smoking.
12
  
Studies have shown a significant trend toward low birth weight with increasing alcohol 
consumption.
13,14,15
 Binge drinking during second trimester was significantly associated with 
small birth size; however, no association was found with alcohol exposure during first 
trimester.
14
  Similar results were found in other studies with a dose-response relationship 
between alcohol consumption and preterm birth, small birth size and low birth weight.
15
   
 Head circumference is included in central nervous system abnormalities due to the effect 
on brain development and cognition.
5 
Alcohol exposure not only affects overall head 
circumference but leads to structural abnormalities in a variety of regions of the brain.  These 
regions include the cerebellum, the corpus callosum, the basal ganglia, and the frontal cortex.
16
 
Research using magnetic resonance imaging (MRI) has shown significant reductions in overall 
brain size and shape, reduction in frontal lobe size, reduction in cerebellar volume, agenesis of 
the corpus callosum, and reduction in size of the basal ganglia.
17
 The damage to the central 
nervous system is thought to be a result of the cytotoxicity and mutagenic nature of ethanol on 
cells.
21
   
 Ultrasound technology could be used as an early predictor of the effects of prenatal 
alcohol exposure on the brain.  Ultrasonography has been used as a tool to identify conditions 
such as Down’s syndrome and lethal trisomies.  Prenatal intracranial measurements, such as 
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frontothalamic distance and caval-calvarial distance have shown significant associations with 
fetal frontal lobe size in fetuses with these syndromes that appear normal on other measures.
42
 
Currently, few studies examine the potential benefit of using this technology to identify the 
effects of alcohol exposure on the developing fetus.   One study showed no association between 
alcohol exposure and head circumference and transcerebellar diameter in utero, however, the 
study did not assess the effect on the frontal cortex.
18
 Another study using similar intracranial 
measurements including frontal lobe measurements showed a significant relationship in the 
variance of frontal lobe size in utero among the alcohol exposed group.
19
  A pilot study from the 
Ukraine further studied this relationship and found significant differences in femur length, caval-
calvarial distance, and frontothalamic distance in alcohol exposed fetuses during second 
trimester ultrasound examinations.  Third trimester ultrasound examinations showed similar 
results for frontothalamic distance and showed a significant reduction in orbital diameter.
20
 
These results are similar to a mouse model showing brain malformations during critical periods 
for neural, ocular and craniofacial development.
43
 
2.3 Prenatal Alcohol Exposure and Infant Development 
 Prenatal alcohol exposure can result in a variety of structural, neurological and functional 
deficits.  The effect of alcohol exposure on the central nervous system has been studied 
extensively over the last 30 years, showing short term and long term cognitive outcomes.  
Neurological damage can include seizures, visual motor difficulties, and motor control issues.
5
   
Seizures have been observed in 3 to 21% of children with FASD’s, with binge drinking during 
early pregnancy resulting in a 3.15 fold increased risk of neonatal seizures.
44,45,46
 Cerebral palsy 
(CP) is an umbrella term for abnormal motor control, and studies have shown a relationship 
between heavy prenatal alcohol exposure and CP.
47,48 
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Neurological and behavioral abnormalities associated with heavy prenatal alcohol 
exposure include overall intellectual performance, attention, learning and memory, language, 
executive functioning, fine and gross motor skills, social skills, and adaptive behavior.
17,21 
 
Neuroimaging studies using magnetic resonance imaging (MRI) have been used to show the 
structural damage to the brain caused by prenatal alcohol exposure.  Numerous studies have used 
imaging to relate the structural damage to the brain with neurological and behavioral deficits in 
children with FAS.
49-53
 According to one study, children with FAS have a mean IQ score of 
approximately 74.
54 
 Additional studies indicate that the average IQ score is between 65 and 72, 
and scores can range from severe mental retardation to normal ranges.
55,56 
 Moderate-to-heavy 
prenatal alcohol exposure can impact learning and memory by reducing the ability to encode 
information rather than retrieve information.
57
   
Individuals with FASD’s also have poor receptive and expressive language skills, which 
may contribute to impaired interpersonal communication.
58 
Individuals with FAS have similar 
attention and activity problems to those with Attention Deficit/Hyperactivity Disorder (ADHD) 
and are often diagnosed with ADHD and prescribed stimulant medication.
59
 Alcohol exposure 
also contributes to adaptive behavior deficits, including daily living skills, socialization, and 
communication, which can be exacerbated by ADHD.
60
 There are distinct differences between 
the pattern of adaptive function deficits between individuals with FAS and those with ADHD, 
and the socialization and communication deficits tend to persist with age for individuals with 
FAS.
61
 Executive function, or higher-order cognitive processes, are significantly impaired in 
individuals with FAS.  Specific executive function deficits include decision making, 
organization, working memory, and set-shifting.
62
 Deficits in non-verbal executive functioning 
can predict poor adaptive behavior in children with both FAS and ADHD.
63
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2.4 Micronutrients and FASD’s 
 Maternal nutrition is required to produce healthy offspring, and pregnant women with 
poor nutritional status deliver children small for gestational age, with physical malformations, 
behavioral disorders, and delayed cognitive development. When nutritional status is 
compromised with alcohol, many essential nutrients are not absorbed, leading to poor 
development for the fetus.
10 
Ethanol alters the uptake of glucose, amino acids and other critical 
nutrients and alters pathways to regulate biochemical processes.
64
 Nutrients such as vitamin A, 
choline, DHA, zinc, and folic acid influence neuronal development in a variety of ways.
10
 
Vitamin A (retinol) is required for cell differentiation and growth, and must be converted 
to a usable form within the liver in order to be absorbed.
65
 Alcohol use during pregnancy can 
reduce the amount of vitamin A available for the fetus by competing for alcohol dehydrogenase, 
the rate-limiting step in retinol oxidation.
66
 Depletion of vitamin A results in reduced cellular 
control and cell signaling in fetal development, and impaired neuronal growth and 
differentiation.  Animal models have shown beneficial results with retinol supplementation 
during pregnancy; however, excess retinol intake can lead to fetal malformations.
65,67
 Therefore, 
vitamin A supplementation programs should be carefully designed. 
Choline and metabolites are required for cell structure integrity, cell signaling, and 
neurotransmission
 
by serving as the precursor to acetylcholine in the developing brain.
68 
Alcohol 
decreases the amount of choline available for these processes by competing for water in choline-
related reactions.
10
 During pregnancy, large amounts of choline are delivered to the fetus across 
the placenta and choline biosynthesis is enhanced. Alcohol exposure reduces the availability of 
methyltetrahydrofolate, the metabolically active form of folate for the human body, increasing 
the demand for choline.
69
 Choline is necessary for neural tube formation in utero, and choline 
11 
 
deficiency can affect stem cell proliferation and increase apoptosis in the brain.
70
 Alcohol creates 
an extra demand for choline during pregnancy which leads to choline deficiency and abnormal 
fetal development.
69
   
Choline supplementation during pregnancy has been studied in both animal and human 
studies.  Animal models using rats have demonstrated conflicting results with some showing 
mitigated spatial memory deficits and others showing no benefits in spatial learning deficits.
71,72
  
Additionally, animal models have shown reduced hyperactivity and behavior alterations.
72,73
  
Choline supplementation also prevented neuronal effects and reduced hypermethylation in the 
hippocampus and pre-frontal cortex of the brain.
74,75 
 An observational study examining the 
effects of choline in pregnancy demonstrated mild increases in child memory and nonverbal 
communication in 7 year old children.
76 
Limited human studies exist relating choline 
supplementation and alcohol exposure, however; the results of a phase 1 clinical trial indicate 
tolerable results with minimal adverse effects.
77
  
Zinc is involved in DNA and RNA stability, RNA polymerase activity, and serves as a 
cofactor in enzyme synthesis, such as superoxide dismutase responsible for preventing apoptosis 
in the brain.
10,78
 Zinc deficiency during pregnancy can produce fetal death, intrauterine growth 
restriction, and teratogenesis, as well as behavioral abnormalities postnatally.
79
 Alcohol 
consumption decreases the amount of zinc available through the placenta, which can result in 
increased embryonic oxidative stress leading to increased apoptosis, and oxidative damage to 
DNA, lipids and proteins.
80
 Animal models studying the relationship between ethanol exposure 
and zinc supplementation demonstrate conflicting results in reduction of physical abnormalities, 
mortality, Purkinje cell loss, and placental uptake.
78,81-83
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Folic Acid (folate) is an essential B vitamin that functions as a coenzyme in nucleic acid 
synthesis and amino acid metabolism.  Folate is also involved in many reactions including DNA 
methylation required for proper cell division.
84
 Folate is responsible for proper fetal growth and 
development and the demand increases during pregnancy.
85
 Animal and cell studies suggest that 
alcohol impairs folic acid transport across the placenta.
86
 Folate deficiency and alcohol 
consumption during pregnancy may also produce neural tube defects, congenital heart defects, 
and limb malformations.
85
 Studies have shown that folic acid may mitigate the effects of alcohol 
use during pregnancy by reducing the oxidative stress to the fetus.
87
 Chronic and heavy alcohol 
use is significantly associated with impaired folate transport, reduced folate in cord blood, and 
reduced cognitive function using Bayley Scales of Infant Development.
85 
One animal study of 
chronic ethanol exposure indicated no significant reduction in teratogenic effects such as growth 
restriction, brain weight, and hippocampus weight with folate supplementation.
88
 However, 
additional animal studies have shown significant reductions in intrauterine growth restriction, 
ethanol-induced cardiac defects, and increased placentation and embryogenesis with folate 
supplementation.
89,90
 Few human studies exist to analyze the mitigating effect of maternal folate 
supplementation on alcohol teratogenesis. 
2.5 The current study  
 The current study aims are (1) to examine the association between alcohol exposure and 
prenatal and postnatal growth and infant development outcomes, and (2) to examine the impact 
of maternal folate levels on the effects of prenatal alcohol exposure.  The impact of alcohol on 
prenatal growth measurements will be obtained through ultrasonography, and will have 
implications for whether the effects of prenatal alcohol exposure can be detected in utero.  The 
effect of micronutrient supplementation and maternal blood folate levels will also be assessed to 
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determine the impact of folate on fetal growth.  We hypothesize that increased levels of alcohol 
exposure will lead to a decrease in head circumference, fetal weight, abdominal circumference, 
femur length, biparietal diameter, and individual brain measurements during second and third 
trimester.  We also hypothesize that fetal growth measurements will be greater among mothers 
who take micronutrient supplementation, and that maternal folate levels in the normal and 
elevated range will relate to greater fetal growth measurements compared to mothers with folate 
in the deficient range.   
 The impact of prenatal alcohol exposure on postnatal growth outcomes including birth 
weight, birth length, birth head circumference, and palpebral fissure length will be assessed and 
compared among micronutrient supplementation groups.  We hypothesize that birth weight, 
length, and head circumference will be lower in the alcohol exposure group, and that 
micronutrient supplementation will relate to increases in these growth measurements.  The 
relationship between maternal folate levels during second and third trimester and birth growth 
outcomes will be also be assessed.  We hypothesize that maternal folate levels in the normal and 
elevated range will lead to greater birth growth measurements compared to those deficient in 
folate.   
 The impact of prenatal alcohol exposure on infant development outcomes including 
Bayley Scales of Infant Development-II Mental Development Index (MDI) and Psychomotor 
Development Index (PDI) will be assessed and compared among groups randomized to 
micronutrient supplementation.  We hypothesize that Bayley MDI and PDI scores will be lower 
in the alcohol exposure group compared to controls and micronutrient supplementation will lead 
to an increase in scores on these measures.  The relationship between maternal folate levels 
during second and third trimester and infant development outcomes will be also be assessed.  We 
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hypothesize that maternal folate levels in the normal and elevated range will lead to greater 
scores compared to those deficient in folate.   
3.1 Methods 
Study Design.   
A prospective cohort study with randomization of maternal nutritional supplements was 
conducted between 2007 and 2012 in two sites of Western Ukraine as part of the Collaborative 
Initiative on Fetal Alcohol Spectrum Disorders (CIFASD).
91
 The study protocol was approved 
by the institutional review board at Lviv Medical University in Ukraine and the institutional 
review board at the University of California, San Diego.  All study participants provided written 
informed consent.  The study recruited 370 women who drank moderate to heavy amounts of 
alcohol during pregnancy, and 322 women who did not drink alcohol during pregnancy.  
Subjects were identified for the alcohol exposure group based on quantity and frequency of 
alcohol consumption during pregnancy.  The women were further separated into micronutrient 
supplement intervention groups in which half of the women within each alcohol exposure group 
were assigned a daily multivitamin supplement (Theravit
®
), and half received standard prenatal 
care.   
At each of the two study sites in Ukraine, standard ultrasound examinations were 
performed throughout pregnancy.  Additional study specific brain growth and facial 
measurements were incorporated during second and third trimester of pregnancy to identify 
alcohol specific fetal growth anomalies.  Blood and urine samples were also taken from women 
during second and third trimester of pregnancy.  Micronutrient concentration including zinc, 
copper, calcium, magnesium, iron, vitamin B12, choline, folate, β-carotene, vitamin C, lycopene, 
15 
 
thiamin, lutein, vitamin D and retinol was assessed.  The blood samples were also tested for 
high-sensitivity C-reactive protein, total protein and triglycerides.   
After birth, information was collected on growth, physical features, and other 
developmental factors.  Growth information included birth weight, birth length, and birth head 
circumference.  Physical feature information including palpebral fissure length, philtrum, and 
upper lip measurements were obtained.  At six-months and twelve-months of age, children were 
invited to return to the study site for developmental assessment using Bayley Scales of Infant 
Development-II.
92 
Study participants 
Women were recruited during their first prenatal visit at two prenatal care facilities in 
Western Ukraine.  From 2007 to 2014, greater than 11,000 pregnant women were screened for 
alcohol use.  The screening instrument was administered by a nurse using a set of 17 questions 
on maternal demographics, tobacco and illicit drug use, medication use, and pregnancy history.  
For those reported as ever using alcohol an additional eight questions were included about 
quantity and frequency of alcohol use.
93
   All women who reported at least weekly binge-
drinking episodes in which 5 or more drinks were consumed, at least 5 episodes in which 3-4 
drinks were consumed, or at least 10 episodes of 1-2 drinks consumed in either the month of 
conception or the most recent month of pregnancy were invited to participate.  The comparison 
group was selected from the non-drinking women meeting screening criteria (no binge episodes 
and minimal or no alcohol use in the month around conception or the most recent month of 
pregnancy) at a 1:1 ratio.   
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After enrollment in the study, an in-person interview by the study nurse at each facility 
was conducted to obtain demographic information including education, occupation, maternal 
age, parity, gravidity, multivitamin use and tobacco use.  Socioeconomic status was calculated 
from education and occupation information using the Hollingshead Scale.
94
   
Measures  
 Independent variables in the analysis include alcohol exposure group identified during 
initial maternal interview as women reporting binge-drinking episodes or heavy alcohol 
consumption in either the month of conception or the most recent month of pregnancy, the 
comparison group was selected from women not meeting screening criteria.  Multivitamin 
supplementation group was randomly assigned at recruitment with half of each alcohol exposure 
group receiving a daily multivitamin supplement (Theravit
®
) and half receiving standard prenatal 
care.  Absolute ounces of alcohol per day at conception is determined from reported type and 
quantity of drinking during each week during the month around conception which is converted 
into absolute ounces of alcohol per week, then divided by seven days.  Serum folate 
concentration (ng/mL) is obtained by blood sample at two time points during pregnancy, 
typically during mid-second trimester and mid-third trimester.  Serum folate concentration 
during each trimester is then categorized into clinically significant blood folate levels with 
elevated blood folate equivalent to >20 ng/mL, normal blood folate equivalent to 6-20 ng/mL, 
and deficient blood folate equivalent to <6 ng/mL.    
 Dependent variables in the analysis include fetal growth, birth growth, and infant 
development outcomes.  Fetal growth measurements were obtained by ultrasound examination at 
initial prenatal visit and follow-up visits during second and third trimester of pregnancy.  
Standard prenatal growth outcomes obtained by ultrasound include head circumference (mm), 
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estimated fetal weight (g), femur length (mm), abdominal circumference (mm), and biparietal 
diameter (mm) measured as the distance between the two parietal eminences.  Additional study 
specific growth measurements were obtained by ultrasound including transverse cerebellar 
diameter (TCD) measured as the maximum diameter between cerebellar hemispheres, 
frontothalamic distance (FTD) measured as the distance between the inner surface of the frontal 
bone to the posterior thalamus, occipitofrontal diameter (OFD) measured as the distance between 
the occipital bone to the frontal bone, caval-calvarial distance (CCD) measured as the distance 
between the inner surface of the frontal bone and the posterior margin of the cavum septi 
pellucidum, and orbital diameter (OD) measurements.  Birth growth outcomes include birth 
weight (g), birth length (cm), birth occipitofrontal head circumference (cm), and palpebral 
fissure length (cm).  Infant development outcomes are measured at 6 and 12 months of age with 
Bayley Scales of Infant Development-II (BSID-II).  The BSID-II Mental Development Index 
(MDI) and Psychomotor Development Index (PDI) assessment measures mental, physical, 
emotional, and social development of children less than three years of age.  
 To address potential confounding, gestational age in weeks at initial maternal interview, 
at exam, or at birth was included in the analysis depending on the outcome of interest.  Child sex 
identified at birth was factored into the analysis along with socioeconomic status based on 
Hollingshead category ratings derived from education and occupation information with one 
being the highest and five being the lowest; Hollingshead categories four and five are considered 
below average socioeconomic status.  Subjects were recruited from two study sites in Ukraine, 
the Rivne Regional Medical Diagnostic Center and the Khmelnytsky Perinatal Center.  Testing 
site was factored into the analysis to control for differences in methods or populations between 
each site.  Maternal smoking status during pregnancy categorized as current smoker, past 
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smoker-quit during pregnancy, past smoker-quit pre-pregnancy, or never smoker was included to 
control for the effect of tobacco use on fetal growth.  Maternal age at interview, gravidity, and 
multivitamin use in early pregnancy were also factored into the analysis. 
  Data Analysis 
 Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) statistical software for windows version 22.0.  Maternal folate levels during second and 
third trimester among alcohol exposed and unexposed pregnancies by multivitamin 
supplementation group was assessed using chi-square tests.  Maternal demographic, nutritional, 
reproductive, and lifestyle characteristics were compared between alcohol exposed and 
unexposed pregnancies by second trimester blood folate levels using ANOVA for continuous 
variables and Chi-square tests for categorical variables.  Maternal demographic, nutritional, 
reproductive and lifestyle characteristics, were compared between alcohol exposed and 
unexposed pregnancies by multivitamin supplementation group using ANOVA for continuous 
variables and Chi-square tests for categorical variables.  Fetal growth outcomes were compared 
using ANCOVA, adjusting for gestational age at exam, among alcohol exposed and unexposed 
pregnancies by multivitamin supplementation group. The association between absolute ounces of 
alcohol per day at conception and fetal growth measurements adjusted for gestational age was 
assessed using simple linear regression.  Birth growth outcomes were compared using 
ANCOVA, adjusting for gestational age at birth, among alcohol exposed and unexposed subjects 
by multivitamin supplementation group.  Gestational age at birth, palpebral fissure length, and 
Bayley Scales of Infant Development at 6 and 12 months of age were analyzed using ANOVA to 
compare alcohol exposed and unexposed subjects and multivitamin supplementation group.  The 
association between absolute ounces of alcohol per day at conception and birth growth 
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measurements adjusted for gestational age, palpebral fissure length, and Bayley Scales of Infant 
Development-II were assessed using simple linear regression.  Variables significantly associated 
with alcohol exposure or absolute ounces of alcohol per day at conception were analyzed using 
generalized linear regression models to assess the impact of alcohol use, multivitamin 
supplementation, and blood folate levels on these outcomes. 
3.2 Results 
 A total of 754 women were recruited from 2008 to 2014, of these women a total of 691 
had live born children.  Among the 691 live infants, a total of 670 mothers had at least one blood 
folate sample, and at least one ultrasound performed.  The alcohol exposure groups consisted of 
306 women with confirmed alcohol use, 49 women with highly suspected alcohol use, and 315 
women with no alcohol use during pregnancy.  The women with highly suspected alcohol use 
were removed from the analysis due to the lack of reliable reporting of alcohol consumption.  
Alcohol use was considered highly suspected by the interview nurse if alcohol use was 
acknowledged but information about timing and quantity of use was not believed to be accurate.  
The first maternal interview was performed at a mean gestational age of 18.57 weeks.  Blood 
samples and ultrasound measurements were taken at interview date and follow-up visits during 
second and third trimester.   
Blood folate levels in alcohol-exposed and unexposed pregnancies by multivitamin 
supplementation group are reported in Table 1.  There was no significant difference between 
blood folate levels in alcohol exposed and unexposed pregnancies by multivitamin 
supplementation group during second trimester; however, blood folate levels were significantly 
different between alcohol exposure groups and multivitamin supplementation groups during third 
trimester (p=0.001).  The alcohol exposure group had a greater percentage of subjects in the 
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deficient range with 26.6% deficient in the MVM supplement group and 45.3% deficient in the 
no MVM supplement group.  Among the alcohol unexposed group, a greater percentage of 
subjects were in the elevated range with 38.4% elevated in the MVM group and 18.2% elevated 
in the no MVM group, and a greater percentage of subjects were in the normal range with 26.5% 
normal in the MVM group and 60.6% normal in the No MVM group. 
Table 1: Blood folate levels in alcohol-exposed and comparison pregnancies, assessed during second and 
third trimester by multivitamin supplementation group. 
Folate Levels Alcohol Exposed 
(n=170)* 
Alcohol Unexposed  
(n=170)* 
Statistic p-value 
 MVM 
Supplement 
(n=95) 
No MVM 
Supplement 
(n=75) 
MVM 
Supplement 
(n=97) 
No MVM 
Supplement 
(n=73) 
  
Second Trimester       
Elevated (>20 ng/mL) 20.0% 20.0% 35.1% 26.0% X
2
(2)<1 NS 
Normal (6-20 ng/mL) 51.6% 57.3% 56.7% 57.5%   
Deficient (<6 ng/mL) 28.4% 22.7% 8.2% 16.4%   
Third Trimester       
Elevated (>20 ng/mL) 25.0% 14.7% 38.4% 18.2% X
2
(2)=13.28 0.001 
Normal (6-20 ng/mL) 48.4% 40.0% 26.5% 60.6%   
Deficient (<6 ng/mL) 26.6% 45.3% 15.1% 21.2%   
* Sample size varies depending on missing values. 
MVM=Multivitamin Supplementation Group 
Maternal demographic, nutritional, health and reproductive characteristics are reported in 
Table 2, by alcohol exposure and blood folate level during second trimester.  Women who drank 
alcohol during pregnancy were more likely to be unmarried, have a greater number of prior 
pregnancies, and less likely to use multivitamins during the first maternal interview before 
enrollment in the study.  Multivitamin supplement use during early pregnancy was significantly 
associated with an increase in blood folate level during second trimester (p<0.001).  Gestational 
age at first maternal interview was significantly associated with both alcohol exposure group and 
blood folate levels (p<0.001), with later gestational age at maternal interview for the alcohol 
exposure group and later gestational age for the deficient and normal blood folate levels 
compared to the elevated group.  Gestational age at second trimester ultrasound was significantly 
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greater in the alcohol exposure group (p=0.011), but was not significantly associated with blood 
folate levels.   
Maternal demographic, nutritional, health and reproductive characteristics are reported in 
Table 3, according to alcohol exposure and multivitamin supplementation group.  Gestational 
age at maternal interview was significantly higher in the alcohol exposed group compared to 
unexposed and significantly lower in the multivitamin supplementation group compared to those 
receiving standard prenatal care (p<0.001).  Serum folate concentration during 3
rd
 trimester visit 
was significantly lower in the alcohol exposure group (p=0.008) and higher in the multivitamin 
supplementation group (p<0.001).  The number of prenatal visits was higher in the no 
supplement group (p=0.002) compared to the supplement group, but not associated with alcohol 
exposure.  The alcohol exposure group had higher number of previous pregnancies on average 
compared to the unexposed group (p=0.024).  
 Fetal growth outcomes, adjusted for gestational age at second trimester ultrasound, for 
alcohol exposed and unexposed pregnancies by multivitamin supplementation group are 
presented in Table 4.  Alcohol exposure was significantly associated with an increase in 
estimated fetal weight (R
2
=0.757, F(1,279)=5.67, p=0.018) at second trimester.  Multivitamin 
supplementation was significantly associated with a decrease in orbital diameter (R
2
=0.273, 
F(1,488)=4.43, p=0.036) at second trimester.  No significant interactions were found between 
alcohol exposure groups and multivitamin supplementation groups during second trimester. 
  Fetal growth outcomes, adjusted for gestational age at third trimester ultrasound, for 
alcohol exposed and unexposed pregnancies by multivitamin supplementation group are 
presented in Table 5.  Alcohol exposure group was significantly associated with a decrease in 
estimated fetal weight at third trimester (R
2
=0.655, F(1,491)=4.02, p=0.045), abdominal 
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circumference at third trimester (R
2
=0.690, F(1,493)=7.02, p=0.008), biparietal diameter at third 
trimester (R
2
=0.529, F(1,493)=7.33, p=0.007), transverse cerebellar diameter at third trimester 
(R
2
=0.552, F(1,399)=8.86,p=0.003), caval-calvarial distance at third trimester (R
2
=0.325, 
F(1,491)=5.46,p=0.020), and orbital diameter at third trimester (R
2
=0.158, F(1,485)=5.72,p=0.017).  
Multivitamin supplementation groups were not significantly associated with any third trimester 
growth outcomes.  No significant interactions were found between alcohol exposure groups and 
multivitamin supplementation groups during third trimester. 
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Table 2: Maternal demographic, nutritional, health and reproductive characteristics by alcohol exposure and blood folate level during second trimester. 
Characteristic Alcohol Exposed (n=170) Alcohol Unexposed (n=170) Statistic p-value 
 Elevated Folate  
>20 ng/mL 
(n=34) 
Normal Folate  
6-20 ng/mL 
(n=92) 
Deficient Folate 
<6 ng/mL 
(n=44) 
Elevated Folate 
>20 ng/mL 
(n=53) 
Normal Folate 
6-20 ng/mL 
(n=97) 
Deficient Folate 
<6 ng/mL 
(n=20) 
  
Unmarried 70.6% 76.1% 59.1% 5.7% 8.2% 10.0% X
2
(2)=8.49 0.014 
Low Socioeconomic Status* 32.4% 28.3% 40.9% 11.3% 19.6% 5.0% X
2
(2)=2.09 NS 
High School Graduate 94.1% 85.9% 95.5% 100% 95.9% 100% X
2
(2)=5.88 NS 
Multivitamin Use during pregnancy 97.1% 63.0% 43.2% 98.1% 75.3% 40.0% X
2
(2)=56.70 <0.001 
Unemployed in last 12 months 32.4% 37.0% 45.5% 43.4% 32.0% 30.0% X
2
(2)=1.07 NS 
Smoker         
Current  17.6% 23.9% 25.6% 0% 2.1% 0% X
2
(6)=7.19 NS 
Past, quit during pregnancy 29.4% 26.1% 30.2% 5.8% 2.1% 0%   
Past, quit pre-pregnancy 17.6% 12.0% 9.3% 9.6% 6.3% 0%   
Never 35.3% 38.0% 34.9% 84.6% 89.6% 100%   
Maternal age (years) 28.06 
(5.59) 
24.97 
(4.88) 
24.52 
(6.09) 
25.17 
(3.53) 
25.63 
(4.74) 
24.05 
(4.35) 
EtOH: F(1,619)<1 
FOL: F(2,337)=2.88 
NS 
NS 
GA at interview (weeks) 15.06 
(4.82) 
18.32 
(5.45) 
20.23 
(5.28) 
16.01 
(3.88) 
17.64 
(5.16) 
18.09 
(4.29) 
EtOH: F(1,619)=30.48 
FOL: F(2,337)=12.04 
<0.001 
<0.001 
GA at 2
nd
 trimester ultrasound 
(weeks) 
20.20 
(1.51) 
21.00 
(2.18) 
21.19 
(2.79) 
20.31 
(1.43) 
20.53 
(1.55) 
20.60 
(1.73) 
EtOH: F(1,503)=6.46 
FOL: F(2,304)=2.80 
0.011 
NS 
Serum folate 2
nd
 trimester (ng/mL) 38.78 
(14.54) 
11.07 
(3.98) 
4.37 
(1.13) 
32.20 
(13.24) 
12.01 
(4.13) 
4.47 
(1.04) 
EtOH: F(1,337)=3.32 
FOL: F(2,336)=357.62 
NS 
<0.001 
Number of prenatal visits 3.79 
(2.54) 
3.98 
(2.31) 
4.18 
(2.39) 
3.60 
(1.96) 
4.15 
(2.66) 
4.30 
(3.37) 
EtOH: F(1,612)<1 
FOL: F(2,337)=1.07 
NS 
NS 
Gravidity 2.44 
(1.62) 
1.99 
(1.29) 
1.86 
(1.59) 
1.85 
(0.84) 
2.00 
(1.37) 
1.40 
(0.60) 
EtOH: F(1,618)=5.12 
FOL: F(2,337)=1.51 
0.024 
NS 
Parity 0.59 
(0.89) 
0.60 
(0.93) 
0.59 
(0.90) 
0.66 
(1.34) 
0.69 
(1.20) 
0.35 
(0.59) 
EtOH: F(1,618)<1 
FOL: F(2,337)<1 
NS 
NS 
  Alcohol use peri-conception 
Oz EtOH/per day  0.715 
(0.637) 
0.596 
(0.498) 
0.554 
(0.408) 
0.005 
(0.028) 
0 0 EtOH: F(1,619)=354.21 
FOL: F(2,337)=1.03 
<0.001 
NS 
Oz EtOH/per drinking day  2.809 
(3.626) 
1.698 
(1.521) 
1.263 
(0.725) 
0.038 
(0.195) 
0 0 EtOH: F(1,619)=276.99 
FOL: F(2,337)<1 
<0.001 
NS 
  Alcohol use first trimester 
Oz EtOH/per day  0.080 
(0.209) 
0.060 
(0.122) 
0.088 
(0.154) 
0 0 0 EtOH: F(1,619)=23.73 
FOL: F(2,337)=1.92 
<0.001 
NS 
Oz EtOH/per drinking day  0.536 
(1.053) 
0.354 
(0.586) 
0.545 
(0.721) 
0.002 
(0.011) 
0 0 EtOH: F(1,619)=98.62 
FOL: F(2,337)=3.11 
<0.001 
0.046 
Values are % or mean (SD).  
GA=Gestational Age; Oz=absolute ounces; EtOH=alcohol exposure groups; FOL=Blood Folate (ng/mL) 
*Socioeconomic status is based on Hollingshead categories 1-5 derived from education and occupation information with 1 being the highest; Hollingshead categories 4 and 5 are 
considered below average socioeconomic status. 
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Table 3: Maternal demographic, nutritional, health and reproductive characteristics by alcohol exposure and multivitamin supplementation group. 
Characteristic Alcohol Exposed (n=306) Alcohol Unexposed (n=315) Statistic p-value 
 MVM supplement 
(n=143) 
No supplement 
(n=163) 
MVM supplement 
(n=159) 
No supplement 
(n=156) 
  
Unmarried 37.8% 35.0% 7.5% 12.8% X
2
(1)<1  NS 
Socioeconomic Status Below average* 39.2% 37.4% 17.6% 14.7% X
2
(1)<1 NS 
High School Graduate 80.4% 88.3% 98.1% 96.8% X
2
(1)=1.44 NS 
Multivitamin Use during pregnancy 54.9% 53.4% 76.7% 67.3% X
2
(1)=2.61 NS 
Unemployed in last 12 months 47.6% 52.1% 38.4% 36.5% X
2
(1)<1 NS 
Smoker       
Current  26.1% 24.5% 0.0% 2.6% X
2
(3)<1 NS 
Past, quit during pregnancy 30.3% 25.8% 3.2% 3.2%   
Past, quit pre-pregnancy 9.2% 11.0% 7.6% 4.5%   
Never 34.5% 38.7% 89.2% 89.6%   
Maternal age (years) 26.11 
(5.82) 
25.98 
(5.81) 
25.87  
(4.29) 
26.47 
(5.04) 
EtOH: F(1,619)<1 
MVM: F(1,619)<1 
NS 
NS 
GA at interview (weeks) 18.62 
(7.02) 
21.16 
(6.54) 
16.74  
(5.57) 
17.70 
(5.44) 
EtOH: F(1,619)=30.48 
MVM: F(1,619)=13.14 
<0.001 
<0.001 
Serum Folate 3
rd
 trimester (ng/mL)  
 
15.35 
(12.18) 
11.07 
(10.36) 
19.83 
(15.54) 
13.33 
(9.64) 
EtOH: F(1,289)=7.15 
MVM: F(1,289)=15.74 
0.008 
<0.001 
GA at 3
rd
 trimester ultrasound (weeks) 33.39 
(2.86) 
33.00 
(2.59) 
33.10 
(2.76) 
32.85 
(2.27) 
EtOH: F(1,494)<1 
MVM: F(1,494)=1.75 
NS 
NS 
Number of prenatal visits 3.46 
(2.43) 
4.24 
(2.35) 
3.71  
(2.53) 
4.19 
(2.83) 
EtOH: F(1,612)<1 
MVM: F(1,612)=9.25 
NS 
0.002 
Gravidity 2.43 
(1.87) 
2.12 
(1.46) 
2.04 
(1.19) 
1.96 
(1.24) 
EtOH: F(1,618)=5.12 
MVM: F(1,618)=2.32 
0.024 
NS 
Parity 0.87 
(1.31) 
0.64 
(0.93) 
0.65 
(0.83) 
0.77 
(1.28) 
EtOH: F(1,618)<1 
MVM: F(1,618)<1 
NS 
NS 
Alcohol use peri-conception 
Oz EtOH/per day  0.691 
(0.634) 
0.616 
(0.589) 
0 0 EtOH: F(1,619)=354.21 
MVM: F(1,619)<1 
<0.001 
NS 
Oz EtOH/per drinking day  1.861 
(2.213) 
1.861 
(1.708) 
0.021 
(0.134) 
0.021 
(0.138) 
EtOH: F(1,619)=276.99 
MVM: F(1,619)<1 
<0.001 
NS 
Alcohol use first trimester 
Oz EtOH/per day  0.137 
(0.347) 
0.241 
(0.901) 
0 0 EtOH: F(1,619)=23.73 
MVM: F(1,619)=2.10 
<0.001 
NS 
Oz EtOH/per drinking day  0.553 
(0.904) 
0.780 
(1.403) 
0 0 EtOH: F(1,619)=98.62 
MVM: F(1,619)=3.65 
<0.001 
NS 
Values are % or mean (SD).  
MVM=Multivitamin supplementation group; GA=Gestational Age; Oz=absolute ounces; EtOH=alcohol.  
*Socioeconomic status is based on Hollingshead categories 1-5 derived from education and occupation information with 1 being the highest; Hollingshead 
categories 4 and 5 are considered below average socioeconomic status. 
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Table 4: Fetal growth outcomes, adjusted for gestational age during second trimester ultrasound, for alcohol 
exposed and unexposed pregnancies by multivitamin supplementation group. 
Outcomes Alcohol Exposed (n=217) Alcohol Unexposed (n=288) Statistic p-value 
 MVM supplement 
(n=108) 
No supplement 
(n=109) 
MVM supplement 
(n=145) 
No supplement 
(n=143) 
  
GA at ultrasound  
(weeks) 
20.87 
(2.26) 
20.74 
(2.10) 
20.42 
(1.37) 
20.37 
(1.43) 
EtOH: F(1,504)=6.44 
MVM: F(1,504)<1 
E&M: F(1,504)<1 
0.011 
NS 
NS 
Head Circumference  
(mm) 
181.69 
(1.09) 
182.31 
(1.09) 
177.11 
(0.87) 
177.28 
(0.87) 
EtOH: F(1,504) <1 
MVM: F(1,504)<1 
E&M: F(1,504)<1 
NS 
NS 
NS 
Estimated Fetal  
Weight (g) 
393.53 
(9.76) 
402.20 
(10.15) 
344.26 
(6.83) 
351.41 
(7.06) 
EtOH: F(1,279)=5.67 
MVM: F(1,279)<1 
E&M: F(1,279)<1 
0.018 
NS 
NS 
Femur Length (mm) 33.56 
(0.27) 
33.87 
(0.27) 
32.68 
(0.23) 
32.92 
(0.23) 
EtOH: F(1,504)<1 
MVM: F(1,504)<1 
E&M: F(1,504)<1 
NS 
NS 
NS 
Abdominal  
Circumference (mm) 
157.66 
(1.06) 
158.80 
(1.06) 
153.22 
(0.83) 
153.02 
(0.83) 
EtOH: F(1,504)=2.26 
MVM: F(1,504)<1 
E&M: F(1,504)<1 
NS 
NS 
NS 
Biparietal Diameter 
(mm) 
49.28 
(0.33) 
49.66 
(0.33) 
48.15 
(0.26) 
47.98 
(0.26) 
EtOH: F(1,504)=1.38 
MVM: F(1,504)<1 
E&M: F(1,504)<1 
NS 
NS 
NS 
Transverse Cerebellar 
Diameter (mm) 
20.95 
(0.36) 
21.30 
(0.41) 
20.50 
(0.28) 
20.58 
(0.35) 
EtOH: F(1,115)=1.87 
MVM: F(1,115)<1 
E&M: F(1,504)<1 
NS 
NS 
NS 
Occipitofrontal  
Diameter (mm) 
63.55 
(0.41) 
63.95 
(0.41) 
62.08 
(0.33) 
62.55 
(0.34) 
EtOH: F(1,493)<1 
MVM: F(1,493)=1.38 
E&M: F(1,493)<1 
NS 
NS 
NS 
Caval-Calvarial  
Distance (mm) 
24.11 
(0.25) 
24.48 
(0.26) 
23.55 
(0.20) 
23.50 
(0.20) 
EtOH: F(1,489)=2.03 
MVM: F(1,489)<1 
E&M: F(1,489)<1 
NS 
NS 
NS 
Frontothalamic  
Distance (mm) 
38.09 
(0.47) 
38.08 
(0.48) 
37.41 
(0.37) 
36.63 
(0.38) 
EtOH: F(1,489)<1 
MVM: F(1,489)<1 
E&M: F(1,489)<1 
NS 
NS 
NS 
Orbital Diameter  
(mm) 
9.99 
(0.13) 
10.13 
(0.13) 
9.60 
(0.10) 
9.89 
(0.10) 
EtOH: F(1,488)=1.30 
MVM: F(1,488)=4.43 
E&M: F(1,488)<1 
NS 
0.036 
NS 
*Sample size may vary due to missing values 
Values are mean (SD) for univariate ANOVA, or mean (SE) for univariate ANCOVA.  
MVM=Multivitamin supplementation groups; GA=Gestational Age; EtOH=alcohol exposure groups; E&M=Interaction between alcohol 
exposure groups and multivitamin supplementation groups. 
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Table 5: Fetal growth outcomes, adjusted for gestational age during third trimester ultrasound, for alcohol exposed 
and unexposed pregnancies by multivitamin supplementation group. 
Outcomes Alcohol Exposed (n=229) Alcohol Unexposed (n=267) Statistic p-value 
 MVM supplement 
(n=114) 
No supplement 
(n=115) 
MVM supplement 
(n=138) 
No supplement 
(n=129) 
  
GA at ultrasound 
(weeks) 
33.39 
(2.86) 
33.00 
(2.59) 
33.10 
(2.76) 
32.85 
(2.27) 
EtOH: F(1,495) <1 
MVM: F(1,495)=1.85 
E&M: F(1,495)<1 
NS 
NS 
NS 
Head Circumference 
(mm) 
302.52 
(1.86) 
299.77 
(1.86) 
303.70 
(1.36) 
301.76 
(1.41) 
EtOH: F(1,493) =3.33 
MVM: F(1,493)=2.03 
E&M: F(1,493)<1 
0.069 
NS 
NS 
Estimated Fetal  
Weight (g) 
2113.24 
(35.12) 
2099.34 
(34.81) 
2141.19 
(21.49) 
2108.77 
(22.32) 
EtOH: F(1,491)=4.02 
MVM: F(1,491)<1 
E&M: F(1,491)<1 
0.045 
NS 
NS 
Femur Length (mm) 62.46 
(0.33) 
62.46 
(0.33) 
62.49 
(0.29) 
62.34 
(0.29) 
EtOH: F(1,493)=1.16 
MVM: F(1,493) <1 
E&M: F(1,493)<1 
NS 
NS 
NS 
Abdominal 
Circumference (mm) 
287.35 
(1.57) 
286.26 
(1.57) 
289.74 
(1.05) 
287.09 
(1.09) 
EtOH: F(1,493)=7.02 
MVM: F(1,493)=2.00 
E&M: F(1,493)<1 
0.008 
NS 
NS 
Biparietal Diameter 
(mm) 
82.78 
(0.45) 
83.47 
(0.45) 
83.81 
(0.33) 
83.76 
(0.34) 
EtOH: F(1,493)=7.33 
MVM: F(1,493) <1 
E&M: F(1,493)=1.12 
0.007 
NS 
NS 
Transverse Cerebellar 
Diameter (mm) 
40.46 
(0.32) 
40.85 
(0.34) 
40.86 
(0.25) 
41.02 
(0.26) 
EtOH: F(1,399)=8.86 
MVM: F(1,399)=1.02 
E&M: F(1,399)<1 
0.003 
NS 
NS 
Occipitofrontal 
Diameter (mm) 
105.67 
(0.51) 
104.84 
(0.51) 
105.25 
(0.48) 
105.08 
(0.50 
EtOH: F(1,487)=1.03 
MVM: F(1,487) <1 
E&M: F(1,487)<1 
NS 
NS 
NS 
Caval-Calvarial 
Distance (mm) 
38.07 
(0.37) 
38.49 
(0.37) 
38.99 
(0.31) 
38.72 
(0.32) 
EtOH: F(1,491)=5.46 
MVM: F(1,491) <1 
E&M: F(1,491)=1.08 
0.020 
NS 
NS 
Frontothalamic  
Distance (mm) 
59.20 
(0.54) 
60.03 
(0.54) 
59.26 
(0.50) 
59.58 
(0.52) 
EtOH: F(1,491) <1 
MVM: F(1,491)=1.22 
E&M: F(1,491)<1 
NS 
NS 
NS 
Orbital Diameter (mm) 15.31 
(0.15) 
15.67 
(0.15) 
15.77 
(0.16) 
15.82 
(0.17) 
EtOH: F(1,485)=5.72 
MVM: F(1,485)=1.71 
E&M: F(1,485)<1 
0.017 
NS 
NS 
*Sample size may vary due to missing values 
Values are mean (SD) for univariate ANOVA, or mean (SE) for univariate ANCOVA.  
MVM=Multivitamin supplementation groups; GA=Gestational Age; EtOH=alcohol exposure groups; E&M=Interaction between alcohol 
exposure groups and multivitamin supplementation groups. 
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 A simple linear regression analysis of the association between absolute ounces of alcohol per 
day at conception and second and third trimester fetal growth outcomes adjusted for gestational age 
are presented in Table 6.  Absolute ounces of alcohol per day at conception is not significantly 
associated with any second trimester fetal growth outcomes; however, there was a significant 
negative association between absolute ounces of alcohol per day and several third trimester fetal 
growth outcomes.  Significant regression equations predicting the effect of absolute ounces of 
alcohol per day on estimated fetal weight (EFW), abdominal circumference (AC), biparietal 
diameter (BPD), occipitofrontal diameter (OFD), and caval-calvarial distance (CCD) were found.  
Estimated fetal weight at third trimester was significantly associated with absolute ounces of alcohol 
per day (R
2
=0.655, F(2,489)=464.887, p<0.001), with a reduction in estimated fetal weight with 
increased alcohol consumption (β=-54.223, p=0.046).  Abdominal circumference at third trimester 
was significantly associated with absolute ounces of alcohol per day (R
2
=0.689, F(2,491)=544.372, 
p<0.001), with a reduction in abdominal circumference with increased alcohol consumption (β=-
3.078, p=0.010).  Biparietal diameter at third trimester was significantly associated with absolute 
ounces of alcohol per day (R
2
=0.532, F(2,491)=278.516, p<0.001), with a reduction in biparietal 
diameter with increased alcohol consumption (β=-1.131, p=0.002).  Occipitofrontal diameter at third 
trimester was significantly associated with absolute ounces of alcohol per day (R
2
=0.493, 
F(2,485)=235.510, p<0.001), with a reduction in occipitofrontal diameter with increased alcohol 
consumption (β=-1.169, p=0.010).  Caval-calvarial distance at third trimester was significantly 
associated with absolute ounces of alcohol per day (R
2
=0.326, F(2,489)=118.435, p<0.001), with a 
reduction in estimated fetal weight with increased alcohol consumption (β=-0.812, p=0.009). 
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Table 6: Simple linear regression analysis to evaluate the association of absolute ounces of alcohol per day at 
conception on second and third trimester fetal growth outcomes adjusted for gestational age. 
Outcomes Second Trimester  Third Trimester 
 β SE p-value β SE p-value 
Head Circumference (mm) 0.605 0.955 NS -2.828 1.472 NS 
Estimated Fetal Weight (g) 17.214 9.680 NS -54.223 27.044 0.046 
Femur Length (mm) -0.132 0.246 NS -0.466 0.279 NS 
Abdominal Circumference (mm) 0.216 0.921 NS -3.078 1.195 0.010 
Biparietal Diameter (mm) 0.016 0.284 NS -1.131 0.355 0.002 
Transverse Cerebellar Diameter (mm) -0.351 0.401 NS -0.470 0.265 NS 
Occipitofrontal Diameter (mm) 0.101 0.359 NS -1.169 0.454 0.010 
Caval-Calvarial Distance (mm) 0.052 0.218 NS -0.812 0.311 0.009 
Frontothalamic Distance (mm) -0.281 0.407 NS -0.833 0.475 NS 
Orbital Diameter (mm) 0.080 0.111 NS -0.231 0.142 NS 
Birth growth outcomes, adjusted for gestational age, and infant development outcomes for 
alcohol exposed and unexposed pregnancies by multivitamin supplementation group are presented in 
Table 7.  Alcohol exposure group was significantly associated with a decrease in gestational age at 
birth (R
2
=0.017, F(1,620)=10.32, p=0.001), a decrease in birth weight (R
2
=0.437, F(1,619)=17.56, 
p<0.001), a decrease in birth length (R
2
=0.437, F(1,619)=9.19, p=0.003), and a decrease in birth head 
circumference (R
2
=0.385, F(1,619)=6.41, p=0.012).  Multivitamin supplementation was not 
significantly associated with birth weight, birth length, or birth head circumference.  There were no 
significant interactions between alcohol exposure groups and multivitamin supplementation groups 
for birth growth outcomes.   
Alcohol exposure group was significantly associated with a decrease in Bayley Scales of 
Infant Development-II MDI scores at 6 months of age (R
2
=0.020, F(1,379)=7.69, p=0.006), a decrease 
in MDI scores at 12 months of age (R
2
=0.022, F(1,292)=7.74, p=0.006), and a decrease in PDI scores 
at 12 months of age (R
2
=0.035, F(1,292)=11.69, p=0.001).  Multivitamin supplementation was not 
significantly associated with Bayley Scales of Infant Development-II scores at 6 or 12 months.  
There was a significant interaction between alcohol exposure groups and multivitamin 
supplementation groups for MDI at 12 months of age (F(1,292)=5.60, p=0.019).  This interaction 
indicates that MDI at 12 months of age, among multivitamin supplementation groups, is 
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significantly different in each alcohol exposure group.  Post-hoc analysis, shown in Figure 1, 
indicates that mean MDI score at 12 months in the alcohol exposure group was higher in the 
multivitamin supplementation group; however, in the alcohol unexposed group, MDI at 12 months 
of age was lower in the multivitamin supplementation group.   
Figure 1:  Mean Mental Development Index (MDI) score at 12 months of age for multivitamin 
supplementation groups by alcohol exposure. 
 
 
82.0
84.0
86.0
88.0
90.0
92.0
94.0
96.0
Alcohol Exposed Alcohol Unexposed
M
ea
n
 M
D
I 
a
t 
1
2
 m
o
n
th
s 
MVM Supplement No MVM Supplement
30 
 
Table 7: Birth growth outcomes, adjusted for gestational age, and infant development outcomes for alcohol exposed and unexposed pregnancies by 
multivitamin supplementation group. 
Outcomes Alcohol Exposed (n=305) Alcohol Unexposed (n=315) Statistic p-value 
 MVM supplement 
(n=142) 
No supplement 
(n=163) 
MVM supplement 
(n=159) 
No supplement 
(n=156) 
  
Child Sex (% Male) 51.0% 50.3% 57.2% 51.9% X
2(1)<1 NS 
GA at birth (weeks) 39.26 
(1.93) 
38.80 
(2.40) 
39.56 
(1.74) 
39.52 
(1.80) 
EtOH: F(1,620)=10.32 
MVM: F(1,619)=2.45 
E&M: F(1,619)<1 
0.001 
NS 
NS 
Birth Weight (g) 3136.42 
(39.54) 
3120.20 
(36.89) 
3379.88 
(32.05) 
3369.22 
(32.36) 
EtOH: F(1,619)=17.56 
MVM: F(1,619)<1 
E&M: F(1,619)<1 
<0.001 
NS 
NS 
Birth Length (cm) 50.65 
(0.23) 
50.70 
(0.21) 
51.86 
(0.17) 
51.81 
(0.17) 
EtOH: F(1,619)=9.19 
MVM: F(1,619)<1 
E&M: F(1,619)<1 
0.003 
NS 
NS 
Birth OFC (cm) 33.85 
(0.14) 
33.78 
(0.14) 
34.58 
(0.11) 
34.29 
(0.11) 
EtOH: F(1,619)=6.41 
MVM: F(1,619)=2.12 
E&M: F(1,619)<1 
0.012 
NS 
NS 
Palpebral Fissure Length (cm) 2.06 
(0.21) 
2.08 
(0.22) 
2.12 
(0.18) 
2.10 
(0.21) 
EtOH: F(1,316)=2.77 
MVM: F(1,316)<1 
E&M: F(1,316)<1 
NS 
NS 
NS 
Bayley Scales of Infant Development-II 
MDI (6 months) 89.18 
(11.00) 
87.83 
(10.03) 
91.54 
(6.31) 
90.56 
(8.18) 
EtOH: F(1,379)=7.69 
MVM: F(1,379)=1.60 
E&M: F(1,379)<1 
0.006 
NS 
NS 
PDI (6 months) 88.34 
(13.75) 
88.13 
(13.89) 
89.69 
(10.48) 
91.17 
(10.15) 
EtOH: F(1,378)=3.04 
MVM: F(1,378)<1 
E&M: F(1,378)<1 
NS 
NS 
NS 
MDI (12 months) 88.99 
(13.48) 
86.75 
(12.60) 
89.56 
(9.15) 
93.84 
(11.89) 
EtOH: F(1,292)=7.74 
MVM: F(1,292)<1 
E&M: F(1,292)=5.60 
0.006 
NS 
0.019 
PDI (12 months) 95.38 
(15.06) 
94.83 
(14.20) 
98.36 
(10.98) 
102.30 
(11.93) 
EtOH: F(1,292)=11.69 
MVM: F(1,292)<1 
E&M: F(1,292)=2.16 
0.001 
NS 
NS 
Values are %, mean (SD) for univariate ANOVA, or mean (SE) for univariate ANCOVA.  
MVM=Multivitamin supplementation groups; EtOH=alcohol exposure groups; E&M=Interaction between alcohol exposure groups and multivitamin supplementation groups; 
GA=Gestational Age; OFC=Occipitofrontal Head Circumference; MDI=Mental Development Index; PDI=Psychomotor Development Index
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A simple linear regression analysis of the association between absolute ounces of alcohol 
per day at conception and birth growth adjusted for gestational age, and infant development 
outcomes are presented in Table 8.  A significant negative association between absolute ounces 
of alcohol per day at conception and birth weight, length, and head circumference was found, as 
well as a significant negative association between absolute ounces of alcohol per day at 
conception and Bayley Scales of Infant Development-II MDI and PDI scores at 6 and 12 months 
of age.  Birth weight was significantly associated with absolute ounces of alcohol per day 
(R
2
=0.437, F(2,617)=239.196, p<0.001), with a reduction in birth weight with increased alcohol 
consumption (β=-136.78, p<0.001).  Birth length was significantly associated with absolute 
ounces of alcohol per day (R
2
=0.439, F(2,617)=241.108, p<0.001), with a reduction in birth length 
with increased alcohol consumption (β=-0.621, p=0.001).  Birth head circumference was 
significantly associated with absolute ounces of alcohol per day (R
2
=0.388, F(2,617)=195.563, 
p<0.001), with a reduction in birth head circumference with increased alcohol consumption (β=-
0.347, p=003).  MDI at 6 months of age was significantly associated with absolute ounces of 
alcohol per day (R
2
=0.069, F(1,378)=28.166, p<0.001), with a reduction in scores with increased 
alcohol consumption (β=-4.226, p<0.001).  PDI at 6 months of age was significantly associated 
with absolute ounces of alcohol per day (R
2
=0.028, F(1,377)=10.730, p=0.001), with a reduction in 
scores with increased alcohol consumption (β=-3.581, p=0.001).  MDI at 12 months of age was 
significantly associated with absolute ounces of alcohol per day (R
2
=0.052, F(1,291)=15.983, 
p<0.001), with a reduction in scores with increased alcohol consumption (β=-4.579, p<0.001).  
PDI at 12 months of age was significantly associated with absolute ounces of alcohol per day 
(R
2
=0.071, F(1,291)=22.384, p<0.001), with a reduction in scores with increased alcohol 
consumption (β=-5.964, p<0.001). 
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Table 8: Simple linear regression analysis to evaluate the association of absolute ounces of alcohol per 
day at conception on birth growth outcomes adjusted for gestational age and infant development 
outcomes. 
Outcomes β SE p-value 
Birth weight (g) -136.78 33.02 <0.001 
Birth length (cm) -0.621 0.184 0.001 
Birth head circumference (cm) -0.347 0.114 0.003 
Palpebral fissure length (cm) -0.027 0.023 NS 
Bayley Scales of Infant Development-II 
Mental Development Index (6 months) -4.226 0.726 <0.001 
Psychomotor Development Index (6 months) -3.581 1.093 0.001 
Mental Development Index (12 months) -4.579 1.145 <0.001 
Psychomotor Development Index (12 months) -5.964 1.261 <0.001 
Generalized linear regression models were used to evaluate the impact of alcohol use, 
multivitamin supplementation, and serum folate concentration on fetal and birth growth 
outcomes and Bayley Scales of Infant Development-II measures significantly associated with 
either alcohol exposure group or absolute ounces of alcohol per day at conception.  Using a 
factorial design, the interaction of these factors and their direct effects on outcomes was 
examined.  Covariates tested for inclusion in the model were gestational age, study site, SES, 
maternal age, child sex, maternal smoking, gravidity, number of prenatal visits, and multivitamin 
use in early pregnancy.   
For fetal growth outcomes at second trimester, estimated fetal weight and orbital 
diameter were analyzed separately.  For estimated fetal weight, the overall model was significant 
(X
2
(8)=203.863, p<0.001).  Only gestational age at interview, number of prenatal visits, and 
gestational age at exam contributed significant variances.  Alcohol exposure groups were 
included in the analysis due to the significant association indicated with ANOVA with estimated 
fetal weight at second trimester.  Alcohol exposure groups, multivitamin supplementation, and 
serum folate concentration were not significantly associated with estimated fetal weight at 
second trimester.   
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For fetal growth outcomes at third trimester, estimated fetal weight, abdominal 
circumference, biparietal diameter, transverse cerebellar diameter, occipitofrontal diameter, 
caval-calvarial distance, and orbital diameter were analyzed separately.  A generalized linear 
regression analysis to evaluate the impact of alcohol use, multivitamin supplementation, and 
serum folate concentration (ng/mL) on estimated fetal weight is presented in Table 9.   For 
estimated fetal weight at third trimester, gestational age adjusted percentiles were included in the 
analysis as response variable and absolute ounces of alcohol per day at conception was included 
in the analysis as predictor.  The overall model was significant (X
2
(7)=18.044, p=0.012), 
multivitamin supplementation group was significantly associated with an increase in estimated 
fetal weight percentile during third trimester (X
2
(1)=5.554, p=0.018), and absolute ounces of 
alcohol per day was significantly associated with a decrease in estimated fetal weight percentile 
(X
2
(1)=5.680, p=0.017).  Serum folate concentration at second and third trimester was not 
significantly associated with estimated fetal weight percentile.  A significant interaction between 
absolute ounces of alcohol per day at conception and serum folate concentration during 2
nd
 
trimester was found (X
2
(1)=4.468, p=0.035); however, the interaction was insignificant after 
reducing to the model to include the interaction and the main effects of absolute ounces of 
alcohol per day and serum folate concentration at second trimester (X
2
(1)=3.786, p=0.052).   
Post-hoc examination of the interaction indicate that absolute ounces of alcohol per day at 
conception is significantly associated with high levels of serum folate (X
2
(1)=8.123, p=0.004), 
but not significantly associated with low levels of serum folate.  The interaction is plotted in 
Figure 2; estimated fetal weight during 3
rd
 trimester tends to be higher at low levels of alcohol 
exposure and lower at high levels of alcohol exposure with high levels of serum folate, indicating 
that folate has a greater effect at low levels of alcohol exposure. 
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Table 9: Generalized Linear Regression Model for estimated fetal weight percentile at third 
trimester ultrasound (X
2
(7)=18.044, p=0.012). 
Variable β SE X2 p-value 
MVM Group
1 
10.588 4.235 5.554 0.018 
AA/Day at conception
 
-18.694 7.844 5.680 0.017 
Serum folate 2
nd
 trimester (ng/mL) -0.259 0.165 2.488 NS 
Serum folate 3
rd
 trimester (ng/mL) 0.260 0.187 1.932 NS 
AA/Day*Folate 2
nd
 trimester
2
 0.898 0.425 4.468 0.035 
AA/Day*Folate 3
rd
 trimester
3
 -0.155 0.461 0.113 NS 
SE=Standard Error; MVM=Multivitamin Supplementation Group; AA/Day at conception=absolute ounces of 
alcohol per day at conception 
1
 No MVM> MVM; 
2 AA/Day*Folate 2nd trimester=Interaction between absolute ounces of alcohol per day at 
conception and serum folate concentration at 2
nd
 trimester; 
3
 AA/Day*Folate 3
rd
 trimester=Interaction between 
absolute ounces of alcohol per day at conception and serum folate concentration at 3
rd
 trimester    
 
Figure 2:  Regression lines for relationships between absolute ounces of alcohol per day at 
conception and estimated fetal weight percentile as moderated by serum folate concentration 
during 2
nd
 trimester. 
 
 
β=unstandardized regression coefficient; SD=Standard Deviation; EFW=Estimated Fetal Weight 
*p<0.05 
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circumference is presented in Table 10.   For abdominal circumference at third trimester, 
gestational age adjusted percentiles were included in the analysis as response variable and 
absolute ounces of alcohol per day at conception was included in the analysis as predictor.  The 
overall model was significant (X
2
(5)=17.955, p=0.003), multivitamin supplementation group was 
significantly associated with an increase in abdominal circumference percentile during third 
trimester (X
2
(1)=7.222, p=0.007).  Increased absolute ounces of alcohol per day resulted in a 
decrease in abdominal circumference percentile (X
2
(1)=5.489, p=0.019).  Serum folate 
concentration during second and third trimester was not significantly associated with abdominal 
circumference percentile during third trimester.  There were no significant interactions between 
absolute ounces of alcohol per day at conception and serum folate concentration during second 
and third trimester. 
Table 10: Generalized Linear Regression Model for abdominal circumference percentile at third 
trimester ultrasound (X
2
(5)=17.955, p=0.003). 
Variable Β SE X2 p-value 
MVM Group
1 
12.062 4.489 7.222 0.007 
AA/Day at conception
 
-9.072 3.872 5.489 0.019 
Serum folate 2
nd
 trimester (ng/mL) 0.018 0.128 0.021 NS 
Serum folate 3
rd
 trimester (ng/mL) -0.001 0.146 0.000 NS 
SE=Standard Error; MVM=Multivitamin Supplementation Group; AA/Day at conception=absolute ounces of 
alcohol per day at conception 
 1
No MVM> MVM.  
For biparietal diameter at third trimester, gestational age adjusted percentiles were 
included in the analysis as response variable and absolute ounces of alcohol per day at 
conception was included in the analysis as predictor.  The overall model was significant 
(X
2
(8)=33.533, p<0.001) with child sex, gestational age at exam, and gravidity contributing 
significant variance.  Multivitamin supplementation group, absolute ounces of alcohol per day, 
and serum folate concentration during second and third trimester were not significantly 
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associated with biparietal diameter percentile.  There were no significant interactions between 
absolute ounces of alcohol per day at conception and serum folate concentration during second 
and third trimester. 
For transverse cerebellar diameter at third trimester, alcohol exposure groups were 
included in the analysis as predictor.  The overall model was significant (X
2
(8)=185.781, 
p<0.001) with child sex, study site, and gestational age at exam contributing significant variance.  
Multivitamin supplementation group, alcohol exposure group, and serum folate concentration 
during second and third trimester were not significantly associated with transverse cerebellar 
diameter.  There were no significant interactions between alcohol exposure groups and serum 
folate concentration during second and third trimester. 
For occipitofrontal diameter at third trimester, absolute ounces of alcohol per day at 
conception were included in the analysis as predictor.  The overall model was significant 
(X
2
(6)=140.231, p<0.001) with gestational age at exam contributing significant variance.  
Multivitamin supplementation group, absolute ounces of alcohol per day at conception, and 
serum folate concentration during second and third trimester were not significantly associated 
with occipitofrontal diameter.  There were no significant interactions between absolute ounces of 
alcohol per day at conception and serum folate concentration during second and third trimester. 
For caval-calvarial distance at third trimester, absolute ounces of alcohol per day at 
conception were included in the analysis as predictor.  The overall model was significant 
(X
2
(8)=115.329, p<0.001) with maternal smoking, study site, and gestational age at exam 
contributing significant variance.  Multivitamin supplementation group, absolute ounces of 
alcohol per day at conception, and serum folate concentration during second and third trimester 
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were not significantly associated with caval-calvarial distance.  There were no significant 
interactions between absolute ounces of alcohol per day at conception and serum folate 
concentration during second and third trimester. 
For orbital diameter at third trimester, alcohol exposure groups were included in the 
analysis as predictor.  The overall model was significant (X
2
(6)=51.545, p<0.001) with 
gestational age at exam contributing significant variance.  Multivitamin supplementation group, 
absolute ounces of alcohol per day at conception, and serum folate concentration during second 
trimester and third were not significantly associated with orbital diameter.  There were no 
significant interactions between alcohol exposure groups and serum folate concentration during 
second and third trimester. 
For birth growth outcomes birth weight, length, and head circumference were analyzed 
separately.  Absolute ounces of alcohol per day at conception were included in the analysis as 
predictor.  A generalized linear regression analysis to evaluate the impact of alcohol use, 
multivitamin supplementation, and serum folate concentration (ng/mL) on birth weight is 
presented in Table 11.   For birth weight, the overall model was significant (X
2
(6)=75.058, 
p<0.001) with gestational age at birth contributing significant variance.  Multivitamin 
supplementation was associated with a significant increase in birth weight (X
2
(1)=5.073, 
p=0.024).  Absolute ounces of alcohol per day at conception and serum folate concentration 
during second and third trimester were not significantly associated with birth weight.  There 
were no significant interactions between absolute ounces of alcohol per day at conception and 
serum folate concentration during second and third trimester. 
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Table 11: Generalized Linear Regression Model for birth weight (X
2
(6)=75.058, p<0.001). 
Variable β SE X2 p-value 
Gestational age at birth 156.640 18.682 70.304 <0.001 
MVM Group
1 
190.446 84.552 5.073 0.024 
AA/Day at conception
 
-103.300 73.745 1.962 NS 
Serum folate 2
nd
 trimester (ng/mL) 1.421 2.460 0.333 NS 
Serum folate 3
rd
 trimester (ng/mL) -2.666 2.749 0.941 NS 
SE=Standard Error; MVM=Multivitamin Supplementation Group; AA/Day at conception=absolute ounces of 
alcohol per day at conception 
 1
No MVM> MVM. 
For birth length, the overall model was significant (X
2
(7)=77.845, p<0.001) with child sex 
and gestational age at birth contributing significant variances.  There were no significant effects 
of absolute ounces of alcohol per day at conception, multivitamin supplementation, or serum 
folate concentration on birth length.  There were no significant interactions between absolute 
ounces of alcohol per day at conception and serum folate concentration during second and third 
trimester. 
For birth head circumference, the final model was significant (X
2
(7)=65.460, p<0.001) 
with child sex and gestational age at birth significantly contributing to the outcome.  There were 
no significant effects of absolute ounces of alcohol per day at conception, multivitamin 
supplementation, or serum folate concentration on birth head circumference.  There were no 
significant interactions between absolute ounces of alcohol per day at conception and serum 
folate concentration during second and third trimester. 
For infant development outcomes only study site, child sex, SES, and gestational age at 
birth contributed significant variance.  Bayley Scales of Infant Development-II MDI scores at 6 
and 12 months and PDI scores at 12 months were analyzed separately.  A generalized linear 
regression analysis to evaluate the impact of alcohol use, multivitamin supplementation, and 
serum folate concentration (ng/mL) on Bayley Scales of Infant Development-II MDI at 6 months 
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of age is presented in Table 12.  For MDI at 6 months of age, the final model was significant 
(X
2
(11)=63.051, p<0.001) with gestational age at birth, study site, SES, and child sex contributing 
significant variance.   There were no significant effects of absolute ounces of alcohol per day at 
conception, multivitamin supplementation, or serum folate concentration during second trimester 
on MDI at 6 months of age.  Serum folate concentration during 3
rd
 trimester was significantly 
associated with an increase in Bayley Scales of Infant Development-II MDI scores at 6 months 
of age.  There were no significant interactions between absolute ounces of alcohol per day at 
conception and serum folate concentration during second and third trimester. 
Table 12: Generalized Linear Regression Model for Bayley Scales of Infant Development-II 
Mental Development Index (MDI) at 6 months of age (X
2
(11)=63.051, p<0.001). 
Variable β SE X2 p-value 
SES Category
1
 17.810 4.842 13.531 <0.001 
Study Site
2 
-5.692 1.511 14.196 <0.001 
Child Sex
3
 -3.850 1.373 7.862 0.005 
GA at birth 1.258 0.458 7.554 0.006 
MVM Group
4 
2.317 1.418 2.672 NS 
AA/Day at conception
 
-1.586 1.542 1.058 NS 
Serum folate 2
nd
 trimester (ng/mL) -0.070 0.049 2.043 NS 
Serum folate 3
rd
 trimester (ng/mL) 0.135 0.062 4.780 0.029 
SE=Standard Error; GA=Gestational Age; SES=Socioeconomic Status; MVM=Multivitamin Supplementation 
Group; AA/Day at conception=absolute ounces of alcohol per day at conception 
1 
Category 1=Highest SES through Category 5=Lowest SES; 
2 
Rivne>Khmelnytsky; 
3
 Female>Male; 
4 
No MVM> 
MVM 
A generalized linear regression analysis to evaluate the impact of alcohol use, 
multivitamin supplementation, and serum folate concentration (ng/mL) on Bayley Scales of 
Infant Development-II PDI at 6 months of age is presented in Table 13.  For PDI at 6 months of 
age, the final model was significant (X
2
(13)=45.637, p<0.001) with SES, study site, and 
gestational age at birth contributing significant variances.  There were no significant effects of 
absolute ounces of alcohol per day, multivitamin supplementation, or serum folate concentration.  
There was a significant interaction between absolute ounces of alcohol per day at conception and 
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serum folate concentration during third trimester (X
2
(1)=5.674, p=0.017).  The interaction 
remained significant after reducing the model to include the interaction and main effects of 
absolute ounces of alcohol per day and serum folate concentration at third trimester (X
2
(1)=4.460, 
p=0.035).  Post-hoc examination of the interaction indicate that absolute ounces of alcohol per 
day at conception is significantly associated with high levels of serum folate (X
2
(1)=3.939, 
p=0.047), but not significantly associated with low levels of serum folate.  The interaction is 
plotted in Figure 3; PDI scores at 6 months of age tend to be higher at low levels of alcohol 
exposure and lower at high levels of alcohol exposure with high levels of serum folate, indicating 
that folate has a greater effect at low levels of alcohol exposure.  
Table 13: Generalized Linear Regression Model for Bayley Scales of Infant Development-II 
Psychomotor Development Index (PDI) at 6 months of age (X
2
(13)=45.637, p<0.001). 
Variable β SE X2 p-value 
Study Site
1 
-8.853 2.360 14.076 <0.001 
SES Category
2 
22.170 7.682 8.329 0.004 
GA at birth 1.959 0.686 8.156 0.004 
MVM Group
3 
2.751 2.843 0.939 NS 
AA/Day at conception
 
-5.333 4.740 1.266 NS 
Serum folate 2
nd
 trimester (ng/mL) -0.109 0.099 1.223 NS 
Serum folate 3
rd
 trimester (ng/mL) -0.026 0.112 0.055 NS 
AA/Day*Folate 2
nd
 trimester
4
 -0.092 0.244 0.144 NS 
AA/Day*Folate 3
rd
 trimester
5
 0.637 0.267 5.674 0.017 
SE=Standard Error; GA=Gestational Age; SES=Socioeconomic Status; MVM=Multivitamin Supplementation 
Group; AA/Day at conception=absolute ounces of alcohol per day at conception 
1 
Rivne>Khmelnytsky; 
2 
Category 1=Highest SES through Category 5=Lowest SES; 
3
 No MVM> MVM;  
4 AA/Day*Folate 2nd trimester=Interaction between absolute ounces of alcohol per day at conception and serum 
folate concentration at 2
nd
 trimester; 
5
 AA/Day*Folate 3
rd
 trimester=Interaction between absolute ounces of alcohol 
per day at conception and serum folate concentration at 3
rd
 trimester. 
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Figure 3:  Regression lines for relationships between absolute ounces of alcohol per day at 
conception and PDI scores at 6 months of age as moderated by serum folate concentration during 
3
rd
 trimester. 
   
β=unstandardized regression coefficient; SD=Standard Deviation; PDI=Psychomotor Development Index 
*p<0.05 
For MDI at 12 months of age, the final model was not significant (X
2
(4)=5.057, p=0.282) 
with no predictors or factors contributing significant variances.  For PDI at 12 months of age, the 
final model was not significant (X
2
(4)=1.758, p=0.780) with no predictors or factors contributing 
significant variances.  There were no significant effects of absolute ounces of alcohol per day at 
conception, multivitamin supplementation, or serum folate concentration on MDI or PDI at 12 
months of age.  There were no significant interactions between absolute ounces of alcohol per 
day at conception and serum folate concentration during second and third trimester. 
3.3 Discussion 
 The lifelong implications of prenatal alcohol exposure are widely studied, with adverse 
effects to physical development, cognition, and behavior.  The teratogenic effect of prenatal 
alcohol exposure on the brain can be extensive with a wide range of possible outcomes.  Fetal 
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growth and brain size, obtained through ultrasound measurements, have not been widely studied 
in alcohol exposed pregnancies.  The impact of micronutrient supplementation and maternal 
folate levels on prenatal alcohol effects has been the focus of animal studies and should be 
analyzed in human studies to determine clinical significance.  This study examined the 
association between alcohol exposure and prenatal and postnatal growth, and infant development 
outcomes as well as the impact of micronutrient supplementation, specifically maternal folate 
levels, on the effects of prenatal alcohol exposure.   
The results from this study support previous research indicating increased risk of growth 
retardation and impaired neurodevelopment with moderate-to-heavy prenatal alcohol exposure.  
The dose and timing of exposure necessary to produce detrimental effects is not clearly 
understood, and the results of this study only lead to further questions.  Alcohol exposure in this 
sample led to prenatal and postnatal growth retardation, as well as impaired neurodevelopment at 
infancy.  Appropriate interventions are necessary to reduce the teratogenic effects of prenatal 
alcohol exposure.  The results of this study provide evidence for the potential benefit of 
multivitamin supplementation during pregnancy, as well as the benefit of high doses of folate 
during pregnancy.  We hypothesized that increased levels of alcohol exposure will lead to a 
decrease in head circumference, fetal weight, abdominal circumference, femur length, and 
individual brain measurements during second and third trimester ultrasounds.  We also 
hypothesized that fetal growth measurements will be greater in the micronutrient 
supplementation group and higher maternal folate levels will lead to greater fetal growth 
measurements.  We hypothesized that birth weight, length, and head circumference will be lower 
in the alcohol exposure group, that micronutrient supplementation will lead to an increase in 
these growth measurements, and that higher maternal folate levels will lead to greater birth 
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growth measurements.  We also hypothesized that Bayley Scales of Infant Development-II MDI 
and PDI scores will be lower in the alcohol exposure group compared to controls, that 
micronutrient supplementation will lead to an increase in scores on these measures, and that 
higher maternal folate levels will lead to greater scores.   
Micronutrient supplementation groups were assigned during initial maternal interview at 
an average of 18.57 weeks gestation.  Blood folate levels during second trimester among alcohol 
exposure groups adjusted for micronutrient supplementation group are not significantly different.  
However, there is a significant difference between blood folate levels in alcohol exposure and 
micronutrient supplementation groups during third trimester.  The lack of effect during second 
trimester is likely due to the fact that the second trimester blood samples were taken at 
approximately the same time as assignment into supplementation groups.  This indicates that 
micronutrient supplementation is having a positive effect on blood folate levels during third 
trimester.  The greater percentage of deficient blood folate levels in the alcohol exposure group 
among those receiving micronutrient supplementation supports previous research indicating 
reduced uptake of folate with alcohol use.
86 
 Absolute ounces of alcohol per day at conception in 
the alcohol exposure group were consistently in the moderate-to-heavy range.  This alcohol 
variable was found to be a greater predictor of outcomes compared to alcohol consumption 
patterns reported during the first trimester of pregnancy.  This finding is consistent with previous 
research indicating a greater willingness of women to report alcohol use prior to pregnancy 
recognition.
95
  
The results of this study indicate that a number of routine ultrasound measurements 
during third trimester of pregnancy may be markers for prenatal alcohol effects in moderate-to-
heavily exposed fetuses.  Estimated fetal weight, abdominal circumference, and biparietal 
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diameter are standard ultrasound measurements obtained during both second and third trimester 
of pregnancy.  Reduced estimated fetal weight during third trimester with increased alcohol 
exposure is consistent with previous findings of reduced birth weight with increased levels of 
alcohol exposure.  Additionally, abdominal circumference was reduced in third trimester 
ultrasound indicating a reduction in overall fetal growth with increased alcohol exposure.  
Smaller biparietal diameter during third trimester is consistent with a previous pilot study in 
Ukraine by Kfir et al, which demonstrated a significant reduction in biparietal diameter during 
third trimester ultrasound.
20
  Biparietal diameter measurements are used to calculate estimated 
fetal weight and gestational age along with head circumference, abdominal circumference and 
femur length.
96
  The use of biparietal diameter to estimate head size and brain volume is widely 
debated; however, previous MRI studies have shown an association between reductions in 
biparietal diameter and delayed cognitive development.
97,98
 The association between alcohol 
exposure and estimated fetal weight, abdominal circumference, and biparietal diameter is a 
potentially important finding due to the availability of these measurements in routine prenatal 
examinations.  With further study, these measurements could be used as markers for the adverse 
effects of prenatal alcohol exposure.   
Additional study specific brain and facial growth measurements including transverse 
cerebellar diameter, occipitofrontal diameter, caval-calvarial distance, and orbital diameter 
showed significant reduction with increased alcohol exposure during third trimester.  The effect 
of alcohol exposure on occipitofrontal diameter indicates an overall reduction in brain size, the 
reduction in caval-calvarial distance indicates a reduction in frontal lobe size, and the reduction 
in transverse cerebellar diameter indicates an effect on size of individual brain structures.
99
 This 
is an interesting finding due to the relationship between the frontal lobe of the brain and many of 
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the cognitive deficits seen in patients with FASD’s.  The effect of alcohol exposure on orbital 
diameter indicates a reduction in eye size during third trimester.  These effects should be further 
studied in a larger sample to determine the clinical significance of this finding, and the potential 
for including these measurements on routine ultrasound examinations. 
The effect of micronutrient supplementation on estimated fetal weight and abdominal 
circumference are also interesting findings.  In this study, the micronutrient supplementation 
group had larger estimated fetal weight and abdominal circumference compared to controls; this 
effect did not extend to biparietal diameter, which was not significantly affected by multivitamin 
supplementation.  There was a significant interaction between estimated fetal weight at third 
trimester, absolute ounces of alcohol per day at conception and serum folate concentration during 
2
nd
 trimester.  Estimated fetal weight tends to be higher at low levels of alcohol exposure and 
lower at high levels of alcohol exposure high levels of serum folate, indicating that folate has a 
greater effect at low levels of alcohol exposure.  This could be due to the impaired uptake of 
folate into the bloodstream and impaired transport of folate across the placenta with high levels 
of alcohol exposure.  Serum folate concentration did not significantly affect any of the fetal 
growth measurements.  There were no significant effects of micronutrient supplementation or 
folate levels on transverse cerebellar diameter, occipitofrontal diameter, caval-calvarial distance, 
and orbital diameter.  This could be a result of the lack of clinically recognized gestational-age 
adjusted growth norms for these measurements.  Gestational-age adjusted growth norms are 
available for standard ultrasound measurements including estimated fetal weight, abdominal 
circumference, femur length, biparietal diameter, and head circumference; there is also limited 
growth norm data for transverse cerebellar diameter, orbital diameter measurements, and 
frontothalamic distance from the 1980’s and early 1990’s.  For frontothalamic distance, the 
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reference values are for fetuses with Down syndrome between 15 and 21 weeks gestation.
100
 It is 
important to establish gestational-age adjusted growth norms for all fetal growth measurements 
in order to correct for rapid growth during second and third trimester.    
The results of this study support previous research indicating a relationship between 
moderate-to-heavy prenatal alcohol exposure, preterm birth, and small for gestational age.  
Alcohol exposure during pregnancy was significantly associated with lower gestational age at 
birth, smaller birth weight, shorter birth length, and smaller birth head circumference.  When 
adjusting for gestational age, micronutrient supplementation was significantly associated with an 
increase in birth weight.  This is similar to results in this study of estimated fetal weight during 
third trimester.  Birth length and head circumference were not significantly associated with 
micronutrient supplementation and serum folate concentration was not significantly associated 
any of these outcomes.  Additional research should be conducted to identify individual 
micronutrients to provide the greatest benefit to birth weight.   
In this study, alcohol exposure significantly decreased infant development scores at 6 
months and 12 months of age.  Serum folate concentration during 3
rd
 trimester was significantly 
associated with an increase in MDI scores at 6 months of age.  Micronutrient supplementation 
was not significantly associated with MDI or PDI scores at 6 months of age.  However, there was 
a significant interaction between PDI at 6 months of age, absolute ounces of alcohol per day at 
conception and serum folate concentration during third trimester, indicating that PDI scores at 6 
months of age at high levels of serum folate tend to be higher at low levels of alcohol exposure 
and lower at high levels of alcohol exposure.  High levels of folate had a greater positive effect 
on PDI at 3
rd
 trimester at low levels of alcohol exposure.  These findings support previous 
research indicating reduced uptake and transport across the placenta of folate with high levels of 
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alcohol exposure.  Micronutrient supplementation and serum folate concentration were not 
significantly associated with MDI and PDI scores at 12 months of age.   A significant interaction 
between MDI scores at 12 months of age, alcohol exposure groups, and micronutrient 
supplementation groups was also found.  The interaction indicated that MDI scores at 12 months 
of age were higher in the multivitamin supplementation group in the alcohol exposed group, but 
lower in the multivitamin supplementation group in the alcohol unexposed group.  These 
findings are consistent with a previous study with the CIFASD consortium in Ukraine which 
found significant reduction in Bayley MDI and PDI scores with increased alcohol exposure.  The 
study also found a significant increase in Bayley MDI scores with multivitamin 
supplementation.
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Folate supplementation during pregnancy in alcohol exposed mice has been the focus of 
many studies; however, few human studies exist.  With further study, the use of maternal folate 
supplementation may have a beneficial effect in alcohol exposed pregnancies.  In addition to 
folate, other micronutrients should be studied to determine the possible benefit of micronutrient 
supplementation in alcohol exposed pregnancies. 
3.4 Limitations and implications 
 There are several limitations to this study.  The absolute amount of alcohol consumed 
throughout pregnancy in the alcohol exposure group is unknown, although the frequency and 
pattern of alcohol use during the month around conception and first trimester was collected 
during maternal interview. The use of maternal self-report of alcohol and tobacco use may not 
represent true consumption levels.  Additionally, maternal alcohol consumption during 
pregnancy may vary between trimesters, leading to inconsistent exposure patterns.  The use of 
absolute ounces of alcohol per day at conception may have provided a more accurate picture of 
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alcohol consumption patterns in the alcohol exposure group; however, it is not possible to know 
if this exposure pattern was consistent throughout pregnancy. There is no known safe level or 
timing for alcohol exposure during pregnancy, therefore, the use of moderate to heavy amounts 
of alcohol at any time point during pregnancy may produce teratogenic effects.   
The maternal characteristics of women who returned for follow-up ultrasound scans and 
blood samples may lead to bias in sampling.  The sample size varied for follow-up examinations, 
which may impact comparability of measurements assessed during second and third trimester.  
The lack of clinically accepted gestational-age adjusted percentiles for study specific fetal brain 
growth measurements may lead to errors in interpretation of the analysis.  Adjustment for 
gestational age is necessary to accurately compare the sample; however, there are few growth 
charts for fetal brain growth measurements available with little reliability.  The growth norm data 
for these ultrasound measurements that is available is outdated and in many cases does not 
account for rapid growth during third trimester.  In order to include these measurements in 
standard clinical practice, clinically accepted gestational-age and gender adjusted percentiles 
must be established. 
This study also has several strengths.  The relatively large sample size provides increased 
statistical power for comparison of alcohol exposed pregnancies and unexposed pregnancies.  
The prospective cohort design provides a temporal sequence between alcohol exposure and 
prenatal outcomes.  The standardized ultrasound measurements are routinely used in a clinical 
setting allowing for reproducibility, and translatability to clinical practice.   
One major implication of this study is that the findings could be used to develop a 
prenatal screening process for pregnancies with known alcohol exposure.  Further study is 
49 
 
needed to determine the reproducibility of these findings; however, the consistency of the results 
with a previous pilot study suggests that biparietal diameter may be a marker for prenatal alcohol 
effects.  The use of maternal micronutrient supplementation as a possible preventive measure for 
the lasting effects of prenatal alcohol exposure is also an important implication.  Additional 
studies should be conducted to identify specific micronutrients and the levels necessary to 
produce the greatest effect.  Early interventions are necessary to improve outcomes in children 
prenatally exposed to alcohol.  The results of this study provide evidence for the need for 
additional early intervention methods, including potential benefits to ultrasonography and 
micronutrient supplementation.   
3.5 Conclusion 
 The results of this study suggest that the effects of prenatal alcohol exposure may be 
detectable in late pregnancy; however, additional studies are needed to determine the reliability 
of these measures.  The data do not presently support adopting clinical standards for prenatal 
ultrasound measurements for early diagnosis of FASD’s.  Additional research into the biological 
mechanism by which alcohol inhibits brain growth is needed to fully understand which areas of 
the brain are most affected by alcohol exposure, and at which level of consumption does this 
effect occur.  The results also support previous research indicating moderate-to-heavy alcohol 
exposure leads to prenatal and postnatal growth restriction as well as impaired 
neurodevelopment.  The data suggest that micronutrient supplementation during pregnancy, 
including high doses of folate, may be an early intervention to reduce the harmful effects of 
prenatal alcohol exposure.  Further studies are needed to identify the specific micronutrients 
producing these effects, and assess the appropriate level of these micronutrients necessary to 
provide the greatest benefit without exceeding the safe limit.  Currently research is being 
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conducted with the CIFASD consortium to examine the effect of prenatal alcohol exposure on 
fetal growth, as well as the potential benefits of maternal micronutrient supplementation on 
FASD’s.   
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Appendix 1: Study sample characteristics. 
 
 
  
>11,000 women screened for alcohol use during first 
prenatal visit. 
Alcohol Exposed Group (N=370): 
At least weekly binge drinking, or 
heavy alcohol use around conception or 
1
st
 trimester 
Alcohol Unexposed Group (N=322): 
No binge drinking or minimal or no 
alcohol use around conception or 1
st
 
trimester 
Infants who died before birth were removed from the analysis. 
Alcohol Exposed Group 
(N=355) 
 
Alcohol Unexposed Group 
(N=315) 
 
Women with “highly suspected alcohol use” were removed from the analysis. 
Alcohol Exposed Group 
(N=306) 
 
Alcohol Unexposed Group 
(N=315) 
 
MVM supplement  
(N=143) 
 
No MVM supplement  
(N=163) 
 
MVM supplement  
(N=159) 
 
No MVM supplement  
(N=156) 
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Appendix 2:  Regression equations for fetal growth measurements at third trimester, birth 
growth measurements, and Bayley Scales of Infant Development-II. 
Predicted estimated fetal weight during third trimester is equal to -3378.466 + 
166.520(Gestational age at exam) – 54.223(absolute ounces of alcohol per day).  Estimated fetal 
weight increased 166.520 g for every week gestation, and decreased 54.223 grams for every 
absolute ounce of alcohol consumed (F(2,489)=464.887, p<0.001, R
2
 = 0.655). 
Predicted abdominal circumference during third trimester is equal to 17.769 + 
8.189(Gestational age at exam) – 3.078(absolute ounces of alcohol per day).  Abdominal 
circumference increased 8.189 millimeters for every week gestation, and decreased 3.078 
millimeters for every absolute ounce of alcohol consumed (F(2,491)=544.372, p<0.001, R
2
 = 
0.689).   
Predicted biparietal diameter during third trimester is equal to 26.749 + 1.726(Gestational 
age at exam) – 1.131(absolute ounces of alcohol per day).  Biparietal diameter increased 1.726 
millimeters for every week gestation, and decreased 1.131 millimeters for every absolute ounce 
of alcohol consumed (F(2,491)=278.516, p<0.001, R
2
 = 0.532).   
Predicted occipitofrontal diameter during third trimester is equal to 37.190 + 
2.067(Gestational age at exam) – 1.169(absolute ounces of alcohol per day).  Occipitofrontal 
diameter increased 2.067 millimeters for every week gestation, and decreased 1.169 millimeters 
for every absolute ounce of alcohol consumed (F(2,485)=235.510, p<0.001, R
2
 = 0.493).   
Predicted caval-calvarial distance during third trimester is equal to 6.388 + 
0.981(Gestational age at exam) – 0.812(absolute ounces of alcohol per day).  Caval-calvarial 
distance increased 0.981 millimeters for every week gestation, and decreased 0.812 millimeters 
for every absolute ounce of alcohol consumed (F(2,489)=118.435, p<0.001, R
2
 = 0.326). 
Predicted birth weight is equal to -3914.216 + 183.587(Gestational age at birth) – 
136.783(absolute ounces of alcohol per day).  Birth weight increased 183.587 grams for every 
week gestation, and decreased 136.783 grams for every absolute ounce of alcohol consumed 
(F(2,617)=239.196, p<0.001, R
2
 = 0.437). 
Predicted birth length is equal to 10.591 + 1.041(Gestational age at birth) – 
0.621(absolute ounces of alcohol per day).  Birth length increased 1.041centimeters for every 
week gestation, and decreased 0.621centimeters for every absolute ounce of alcohol consumed 
(F(2,617)=241.108, p<0.001, R
2
 = 0.439). 
Predicted birth head circumference is equal to 11.368 + 0.582(Gestational age at birth) – 
0.347(absolute ounces of alcohol per day).  Birth head circumference increased 0.582 
centimeters for every week gestation, and decreased 0.347 centimeters for every absolute ounce 
of alcohol consumed (F(2,617)=195.563, p<0.001, R
2
 = 0.388). 
Predicted MDI score at 6 months of age is equal to 91.208 – 4.226(absolute ounces of 
alcohol per day).  MDI score at 6 months of age decreased 4.226 points for every absolute ounce 
of alcohol consumed (F(1,378)=28.166, p<0.001, R
2
 = 0.069). 
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Predicted PDI score at 6 months of age is equal to 90.516 – 3.581 (absolute ounces of 
alcohol per day).  PDI score at 6 months of age decreased 3.581 points for every absolute ounce 
of alcohol consumed (F(1,377)=10.730, p=0.001, R
2
 = 0.028). 
Predicted MDI score at 12 months of age is equal to 91.311 – 4.579(absolute ounces of 
alcohol per day).  MDI score at 12 months of age decreased 4.579 points for every absolute 
ounce of alcohol consumed (F(1,291)=15.983, p<0.001, R
2
 = 0.052). 
Predicted PDI score at 12 months of age is equal to 99.760 – 5.964(absolute ounces of 
alcohol per day).  PDI score at 12 months of age decreased 5.964 points for every absolute ounce 
of alcohol consumed (F(1,291)=22.384, p<0.001, R
2
 = 0.071). 
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Appendix 3:  Post-hoc analysis of interactions 
Regression equation for PDI at 6 months of age with main effects and interaction: 
PDI6mo = 93.764 – 8.009 (AA/day) – 0.127 (Folate2) + 0.502 (AA/day*Folate2) 
Regression equation for PDI at 6 months of age with main effects and interaction (with centered 
variables): 
 PDI6mo = 91.705 – 0.423 (AA/day) + 0.034 (Folate2) + 0.502 (AA/day*Folate2) 
High Folate 3
rd
 trimester (with centered variables): 
PDI6mo = 91.265 – 6.828 (AA/day) + 0.034 (Folate2above) + 0.502 
(AA/day*Folate2above)    
Overall model: X
2
(3)=4.831, p=0.185.  AA/day: X
2
(1)=3.939, p=0.047. 
With 0 for Folate 2 above 1 SD: 
PDI6mo = 91.265 – 6.828 (AA/day)  
PDI6mo = 91.265 – 6.828 (0.859363) = 85.39726944 
PDI6mo = 91.265 – 6.828 (0.32221) = 89.0649501 
PDI6mo = 91.265 – 6.828 (-0.214943) = 92.7326308 
Low Folate 3
rd
 trimester (with centered variables): 
PDI6mo = 92.145 + 5.983 (AA/day) + 0.034 (Folate2below) + 0.502 
(AA/day*Folate2below)     
Overall model: X
2
(3)=4.831, p=0.185.  AA/day: X
2
(1)=1.921, p=0.166. 
With 0 for Folate 2 below 1 SD: 
PDI6mo = 92.145 + 5.983 (AA/day)  
PDI6mo = 92.145 + 5.983 (0.859363) = 97.2865688 
PDI6mo = 92.145 + 5.983 (0.32221) = 94.0727824 
PDI6mo = 92.145 + 5.983 (-0.214943) = 90.858996 
 
Regression equation for Estimated Fetal Weight at 3
rd
 trimester with main effects and 
interaction: 
EFW = 52.237 – 17.148 (AA/day) – 0.170 (Folate1) + 0.690 (AA/day*Folate1) 
Regression equation for Estimated Fetal Weight at 3
rd
 trimester with main effects and interaction 
(with centered variables): 
 EFW = 47.546 – 6.051 (AA/day) + 0.052 (Folate1) + 0.690 (AA/day*Folate1) 
High Folate 2
nd
 trimester (with centered variables): 
EFW = 46.841 – 15.429 (AA/day) + 0.052 (Folate1above) + 0.690 
(AA/day*Folate1above)    
Overall model: X
2
(3)=8.041, p=0.045.  AA/day: X
2
(1)=8.123, p=0.004. 
With 0 for Folate 1 above 1 SD: 
EFW = 46.841 – 15.429 (AA/day)  
EFW = 46.841 – 15.429 (0.859363) = 33.58188827 
EFW = 46.841 – 15.429 (0.32221) = 41.86962191 
EFW = 46.841 – 15.429 (-0.214943) = 50.15735555 
Low Folate 2
nd
 trimester (with centered variables): 
EFW = 48.252 + 3.326 (AA/day) + 0.052 (Folate1below) + 0.690 
(AA/day*Folate1below)     
Overall model: X
2
(3)=8.041, p=0.045.  AA/day: X
2
(1)=0.237, p=0.626. 
With 0 for Folate 1 below 1 SD: 
EFW = 48.252 + 3.326 (AA/day)  
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EFW = 48.252 + 3.326 (0.859363) = 51.44024134 
EFW = 48.252 + 3.326 (0.32221) = 49.32367046 
EFW = 48.252 + 3.326 (-0.214943) = 47.53709958 
 
